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Chapter 1: introduction 
Introduction 
Communication between cells or tissues is essential to the viability of 
multicellular organisms. One mechanism by which cells communicate is through 
the secretion of growth factors or hormones, which travel through body fluids and 
bind to receptors on the surface of target cells. The binding of growth factors to 
specific cell surface receptors induces a cascade of intracellular events that 
often results in an altered profile of gene expression in the target cell. The 
products of these newly induced genes may then effect further changes within 
the target cell, including cell growth, differentiation, migration, or even 
programmed celT death. Often, the binding of a hormone or growth factor to its 
cognate receptor will result in increased synthesis and secretion of other growth 
factors, which, upon release, can induce even further physiological effects 
beyond those immediate responses elicited by the original growth factor. Growth 
hormone, for example, expressed in the anterior pituitary gland during childhood, 
binds to receptors on the liver and stimulates expression of insulin like growth 
factor I (IGF 1). IGF 1 then binds to IGF receptors displayed on t>one cells to 
promote skeletal growth. A defect in the ability to produce growth hormone leads 
to reduced levels of IGF, which in tum slows skeletal growth, finally resulting in 
dwarfism (1). These types of interactions between different tissues that are 
coordinated by growth factors, are essential to normal growth, development, and 
reproduction of multicellular organisms. Therefore, it is important to unravel the 
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complex mechanisms by which growth factor signalling is regulated in order to 
understand how communication between cells or tissues relates to development 
and disease. 
A major component of growth factor regulation is the tissue and temporal, 
specific expression of the growth factor. This control is often achieved through 
the differential expression of transcription factors that regulate expression of the 
certain genes encoding growth factors. The subset of transcription factors 
expressed in a cell and their activities are determined by the cell type and the 
external stimuli the cell receives. Transcriptional activation of a gene will occur 
through complex interactions t>etween cell specific and ubiquitous transcription 
factors that bind to the promoter and surrounding sequences of the gene to 
promote RNA polymerase activity. In this manner, a cell type may be 
predisposed, based upon the cell specific transcription factors it contains, to 
transcribe and express a particular growth factor gene when induced by the 
correct stimuli. 
The overall purpose of the research presented here is to investigate the tissue 
specific regulation of a subset of genes in the Growth Hormone/Prolactin 
(GH/PRL) family called Mitogen Regulated Protein (MRP; also known as 
Proliferin (PIf) and collectively as mrp/plfs. (Linzer and Nathans, 1984; Nilsen-
Hamilton et al., 1980; Parfett et al., 1985). Previous to the reports included in this 
thesis, the only identified source of/n/p/)3/f expression In vivo, were the 
trophoblastic giant cells of the placenta (Lee et al., 1988). These cells lie at the 
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interface between the fetal placenta and maternal decidua, where they also 
produce several other QH/PRL family memt)ers (Soares et a/., 1998). During 
mid-gestation, giant cells secrete high levels of MRP/PLF (Lee et al., 1988; 
Linzer et al., 1985; Nilsen-Hamilton et al., 1988), where it is t)elieved to act as 
both a placental angiogenesis factor (Jackson etal., 1994; Volpert etai., 1996) 
and a uterine growth factor (Fang eta/., 1999; Nelson etal., 1995). MRP/PLF is 
also released into the maternal and fetal circulation. There is evidence that 
PLF1 binds to the mammary gland (JN ; Thesis) and the fetal heart (Jackson and 
Linzer, 1997). Thus, MRP/PLF is probably a fetal growth factor involved in 
coordinating maternal and fetal development during pregnancy. 
Unlike other memt)ers of the GH/PRL family, which were originally identified in 
the pituitary or placenta, MRP/PLFs were originally kientified as a family of 
glycoproteins secreted by growth factor stimulated NIH 3T3 cells, which are a 
cell type derived from fetal mesenchymal ceils (Nilsen-Hamilton et al., 1980). 
Further investigations have confirmed that mrp/plfs are secondary response 
genes upregulated by growth promoting agents in 3T3 cells and some other 
immortalized cell lines. (Chiang and Nilsen-Hamilton, 1986; Gil-Torregrosa etal., 
1994; Linzer D.I.H., (1984).; Linzer and Wilder, 1987; Parfett etal., 1985). 
Southern blot analysis has revealed that there are between 4 and 6 mrp/plf 
genes in the mouse genome (Jackson-Grusby etal., 1988) and three separate 
but highly homologous mrp/plf promoters (96-98% identical) have t)een cloned 
(Connor et al., 1989; Linzer and Mordacq, 1987). Three different mrp/plf cDUAs 
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have been identified as well (P/ff, Plf2, and mrp3), which retain 96-98% 
homology, but only one of these {mrp3) has been linked to a cloned 
promoter.(Connor et a/., 1989; Linzer and Mordacq, 1987; Wilder and Linzer, 
1986). M/p/p/f promoters fused to reporter genes are regulated in transfected 
cells in response to serum or growth factors (Connor et a!., 1989; Groskopf and 
Linzer, 1994; Linzer and Mordacq, 1987; Mohideen etaL, 1999). However, 
despite extremely high homology amongst the three cloned mrp/plf promoters 
(98%) these promoters behave differently in response to various stimuli (Conner, 
1986; Linzer and Mordacq, 1987; Mohkleen, 1995; Mohideen eta!., 1999). 
Furthermore, previous reports have shown that 3T3 cells only produce p/f1 
mRNA (Mohideen, 1995), while the placenta produces at least three different 
mq /^plf mRNAs (Mohideen, 1995; Wilder and Linzer, 1986). These observations 
suggested that individual endogenous mrp/plf genes are regulated differently 
from one another. 
The observations described here suggest that elements within the mrp/plf 
promoters or surrounding sequences regulate tissue specific mrp/plf expression. 
To gain a better understanding of tissue specific regulation of mrp/plf gene 
expression the following questions were considered. 1) Which of the three to six 
possible mrp/plf genes are expressed in the giant cells; 2) What is the 
significance of multiplicity of highly similar mrp/plf genes? 3) Are different forms 
of mrp/plf expressed in particular temporal or tissue specific pattems, as is found 
with other genes for which there are multiple isoforms? 4) How is mrp/plf 
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expression directed specifically to the trophoblastic giant cellsThe research 
described in this manuscript was designed to answer these questions. 
To answer the questions posed in the previous paragraph, we have designed a 
quantitative method to determine the relative levels of different mrp/plf RNA 
species in a sample. We have used this assay to identify the major placental 
species and have demonstrated that different mrp/^ lfisoforms are temporally 
regulated during gestation. Furthermore, this assay was used to identify a fourth 
previously undescrit>ed mqj/ptf species {mrp4) which I cloned and characterized 
in terms of its tif sue specific and temporal expression pattern. I also 
demonstrate that expression is not limited to the placenta, and that 
despite 97% sequence identity in the proximal promoter sequences, different 
forms of mrp/ptfsixe indeed expressed in a tissue specific fashion in the adult 
mouse. Different pattems of expression were found in a number of adult 
epithelial tissues including the lining of the alimentary tract, the hair follicles, the 
tail and ear skin, and in healing skin wounds. expression during different 
stages of wound healing and hair follicle growth was further investigated and was 
shown to be dynamically regulated during the healing process and through the 
hair follicle cycle respectively. Furthermore, primary cultures of mouse 
keratinocytes showed regulated expression of mrp/plfs in response to growth 
factors that are expressed during wound healing. 
To better understand the mechanisms by which mrp/p/f expression is 
regulated in vivo, mrp3 promoter/lacZ constructs were analyzed in cell culture 
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and in transgenic mice. It was demonstrated that 1450 b.p. mrp3 5' flanking 
sequence and 3000 b.p. of 3' sequences were sufficient to express detectable 
levels of p-galactosidase in transient transfection of giant cells or fibroblasts, but 
were unable to direct detectable reporter gene expression in transgenic embryos. 
A possible explanation for these results is that mrp3 promoter activity is inhibited 
when integrated into chromatin. To determine if a strong enhancer could 
overcome the inhibition by chromatin, the CMV immediate early enhancer was 
added to the 5' end of the transgene. The CMV/mrp3/lacZ transgene was able to 
direct expression of P-galactosidase activity in mid-gestational embryos and in 
the adult mouse, which paralleled expression of the endogenous mrpS. We 
further demonstrated that removal of 5' or 3' mrpS sequences results in a higher 
level of non-specific expression more similar to the described expression pattern 
of CMV enhancer/promoter transgenes. This suggests that mrp/p/f sequences in 
the transgene are able to direct tissue specific expression, but additional 
sequences are necessary to overcome inhibitory chromatin structure. Of 
significance is the finding that mrp3 sequences can direct tissue specific 
expression in the presence of an enhancer that is nearly ubiquitously active. The 
mechanism of tissue specific expression in the presence of a enhancer which is 
ubiquitously active is further investigated in this thesis. 
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Dissertation organization 
The author did all of the research described in this thesis. The thesis is 
divided into five chapters. Chapter 1 is a general introduction to the project. 
Chapter 2 is literature review, in which background information regarding 
MRP/PLF is discussed. Chapters 3 through 5 are in the form of journal papers. 
In chapter 3 is described the analysis of which mrp/pif forms are expressed in the 
placenta and the identification and characterization of mrp4, a newly discovered 
mrp/plf family memt)er with a distinct tissue and temporal specific regulation. 
Chapter 4 describes an investigation of the regulation of m/p/p/f expression 
during the hair follicle cycle and in healing skin wounds of the mouse. In chapter 
5 is described the investigation of mrp3 promoter regulation using transgenic 
mice and cultured cells. Chapter 6 is a discussion and interpretation of the 
results obtained in chapters 3 through 5 based on current understanding of the 
field. This chapter remarks on the significance of the findings presented and 
suggests further directions for this research. An appendix is also provided which 
includes other data obtained by the author that supports the thesis but is not 
Included in papers to be published. 
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CHAPTER 2: LITERATURE REVIEW 
Identification of MRP/PLF, a member of the proiactin/growth hormone 
family 
Mitogen Regulated Protein (MRP) was originally identified by Marit Nilsen-
Hamiiton as a 34 kd glycoprotein secreted by immortalized mouse embryo 
fibroblasts (3T3 cells) in response to mitogen stimulation (Nilsen-Hamiiton eta!., 
1980). The cONA was later independently isolated from a library containing 
cDNAs of NIH 3T3 cell RNAs upregulated in response to serum stimulation. 
These investigators called this mRNA pmliferin (Linzer and Nathans, 1984). 
Because MRP and proliferin are the same (Nilsen-Hamiiton etai, 1987), the 
terms mrp/plf, and MRP/PLF will be used as a general reference to the genes or 
mRNAs and the proteins respectively. Specific genes and their products will be 
identified by their individual names such as mrp3, plf1, or plf2. 
When the cONA of pifl was sequenced, it was found to have 55% nucleotide 
sequence identity with the coding region of bovine prolactin. Similarily, the open 
reading frame predicted a protein of 234 amino acids that had 22% homology to 
bovine growth hormone and 37% homology to bovine prolactin (Linzer and 
Nathans, 1984). The predicted structure of MRP/PLF is also similar to GH/PRL 
proteins, containing conserved locations of cysteines that are proposed to 
determine GH and PRL secondary structure (Dai etal., 1996). The gene 
13 
structure of mrp/plf \s similar to other members of the family; being 
composed of four Introns and five exons (Connor et al., 1989). An important 
difference however, is that the MRP/PLFs, in contrast to GH and PRL, are 
always found glycosylated (Nilsen-Hamilton etal., 1981; Nilsen-Hamilton eta!., 
1980)Lee and Nathans, 1987). This post-translational modification has a 
significance that may be related to the functions of MRP/PLFs and will be 
discussed later. Because MRP/PLFs resemble GH/PRL in sequence and 
structure, yet do not bind to the GH/PRL receptors(Lee and Nathans, 1988), 
MRP/PLFs have been classified as a "non-classical" member of the gh/pr! gene 
family. 
The mrp/plf genes are located in a duster on chromosome 13 of the mouse. 
This chromosome also harbors mouse placental lactogens I and II, proliferin 
related protein, and genes for at least 5 different prolactin-like proteins (Linzer 
and Fisher, 1999; Scares et al., 1998). These genes are believed to t>e a result 
of duplications of the prolactin gene, which is also located on chromosome 13 
(Jackson-Grusby etal., 1988). All of these genes, including mrp/plf, are 
expressed in the placenta or uterus and for many of these genes, these tissues 
are the only known location of their expression.(Faria et al., 1991; Linzer et al., 
1985; Muiler et al., 1998a; Muller et al., 1998b; Nilsen-Hamilton et al., 1991; Toft 
and Linzer, 1999; Yamaguchi etal., 1994) and (Linzer and Fisher, 1999; Soares 
et al., 1998) for review. At this time, a human MRP/PLF has not been identified. 
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However, humans have independently evolved placental specific members of 
the GH/PRL family from the growth hormone gene rather than the prolactin gene 
(Owerbach et al., 1980), and these hormones may perform some of the functions 
of the MRP/PLF. 
Like other members of the GH/PRL family, gene duplication of mrp/plf has 
occurred. There are an estimated 4-6 mrp/plf genes based on Southern blot 
analysis (Jackson-Grusby etal., 1988), and three different cDNAs {mrp3, plf1 
and plf2) have been identified. The pifl cONA was isolated from 3T3 cells 
((Linzer and Nathans, 1983; Linzer and Nathans. 1984)), The plf2 cDIMA was 
isolated from Balb/c mouse placentae (Wilder and Linzer, 1986), and the mrp3 
cDNA is predicted from the sequence of the mrp3 gene, based on the 
exon/intron boundaries (Connor et al., 1989). Another form of mrp/plf mRNA 
exists as well in Ehrlich ascites carcinoma cells. This form is a splice variant of 
plf1 (Torregrosa B.G., (1994).). The different mrp/plf cDf4As have 97-98 % 
nucleic acid identity, as do the first 600 bp of the three promoters that 
have been cloned (Connor ef a/., 1989; Linzer and Mordacq, 1987). Only the 
mrp3 promoter has been linked to a specific cONA (mrp3) (Connor et al., 1989). 
The significance of multiple similar genes is not known but it appears that 
despite few differences in sequence, the three mrp/plf promoters are regulated 
differently in transfected cells (Linzer and Mordacq. 1987; Mohideen et al., 
1999). Linzer et al. (Linzer and Mordacq, 1987) reported that 1100 bp of the 
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promoters that he designated plf42 and plf149 were both active in transfected 
mouse L cells, but only the plf42 promoter showed induction in response to 
serum. Similariiy, Mohideen et al. showed that in 3T3 cells, the mrp3 promoter 
was upregulated in response to fibroblast growth factor 2 (FGF2}, while the plf42 
and plf149 promoters were not (Mohideen et al., 1999). These differences in 
response to stimulation with various mitogens could reflect properties of the 
mqj/plf genes that allow tissue specific or temporal regulation of expression of 
particular mrp/plf species in response to various stimuli. Tissue specific or 
temporal activity of different m/p/js/f promoters or genes in vivo, however, has not 
yet been reported. 
Tissue specific expression and functions of NIRP/PLFs 
MRP/PLF was discovered in growing, immortalized mouse embryo fibroblast 
cells (3T3 cells) and can also be found in several other immortalized cell lines 
(Linzer D.I.H., (1984).; Parfett et ai, 1985) derived from other mouse tissues. 
But, it is not detectable in primary cultures of mouse embryo fibroblasts, the 
cultures from which 3T3 cells were derived (Parfett etaL, 1985). A study to 
investigate where mrp/plfv/as expressed in vivo, a survey of adult and fetal 
tissues by Northern blot analysis revealed the placenta as the only tissue that 
contained detectable levels of mrp/plfmRNA (Linzer et a!., 1985). 
In the placenta. MRP/PLF protein and mRNA are localized specifically in the 
trophoblastic giant cells (Lee et al., 1988). Upon differentiation, trophoblastic 
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giant cells cease dividing, but continue to replicate their DNA, becoming very 
large polyploid cells that contain up to 1000 times the haploid amount of DNA 
(Barlow, 1972; Zybina, 1970). Giant cells are located in the outermost fetal 
layer of the placenta in direct contact with matemal tissue and are proposed to 
serve as a protective and selective barrier between the mother and the fetus 
(Hoffman L.H., 1993). From this location, giant cells produce MRP/PLFs at peak 
levels during midgestation (el0-11) at which time it is secreted to reach up to 5 
ug/ml into the matemal bloodstream and 0.8 ug/ml into the amniotic fluid (Lee 
and Nathans, 1987). MRP/PLF is considered a non-classical member of the 
PRL/GH family in that it does not bind to the GH or PRL receptor (Lee and 
Nathans, 1988). This suggested that MRP/PLF functions through a different 
receptor and could have separate activities from classical memt}ers of the 
GH/PRL family. Indeed, Jackson et al. have shown that plf1 has angiogenic 
properties and can bind endothelial cells in the placenta, suggesting it is a 
placental angiogenesis factor (Jackson etal., 1994). This activity is mediated 
through the cation independent IGFII/mannose 6-phosphate receptor that is 
activated by mannose 6-phosphate residues on glycosyl groups of p/fY (Volpert 
et al., 1996). Interestingly, the mannose residues on circulating MRP/PLF in the • 
matemal serum are not phosphorylated (Adnan Mubaidin and Yu Fang, 
unpublished results), so the mannose 6-phosphate activity of MRP is likely to be 
a very local effect upon only the placenta. However, Nelson et al. have shown 
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that MRP/PLF also binds to a receptor in the uterus that is different from the 
mannGse-6 phosphate receptor. This receptor is temporally regulated with the 
highest expression occum'ng at the same time MRP/PLF is most strongly 
expressed (e11) (Nelson et al., 1995). Importantly, this report also shows that 
MRP/PLF stimulates DNA synthesis in primary uterine cell cultures, suggesting 
that MRP/PLF Is a uterine growth factor. These results provide evidence that 
MRP Is a fetal protein that probably plays a role in coordinating fetal/matemal 
interactions during pregnancy.(Fang eta/., 1999) 
Finally, there is another possible function of MRP/PLFs. That is, as an 
intracellular repressor of muscle cell differentiation. Wilder et al. showed that 
over expression of PLF1 in an immortalized myogenic cell line (23A2) can 
prevent muscle cell differentiation, but PLF2 does not have this effect (Wilder 
and Linzer, 1989). The expression of PLF1 in muscle cells apparently decreases 
the level of cARG transcription factor, which activates genes associated with 
myogenic differentiation (Muscat et al., 1991). 
While it is now well established that members of the mrp/plf family are 
expressed strongly in the placenta, the levels and temporal regulation of 
individual mrp/plf fonus in the placenta have not t>een thoroughly investigated. 
Linzer and colleagues have presented evidence using oligonucleotides specific 
for plf2 or plf1 are both of these genes are expressed in the placenta (Wilder and 
Linzer, 1986), and Mohideen, using an RT-PCR-restriction analysis assay, has 
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shown evidence for the presence of all three known cDNAs in the placenta 
(Mohideen, 1995). However, neither of these studies were quantitative, nor were 
they performed at multiple stages during the time course of expression. 
Because different MRP/PLFs may have different functions (Wilder and Linzer, 
1989), and the promoters for the different m/p/p/f genes appear to be regulated 
differently in vitro (Linzer and Mordacq, 1987; Mohideen et al., 1999), it would be 
of interest to accurately determine the expression patterns of different mrp/ptk in 
vivo. This would further be of value if the particular promoters which have been 
Identified {mrp3, plf42, and ptf149) could be linked to tissue specific or temporally 
regulated mRNAs, as previous work investigating the regulation of these 
promoters could provide clues as to what factors may regulate the activities of 
the promoters in vivo. 
The regulation of MRP/PLF expression in cultured cells 
Studies regarding regulation of m/73/p/f expression were initiated when it was 
found that secreted MRP/PLF levels increase substantially in response to 
mitogenic stimulation (Nilsen-Hamilton etaL, 1980). These mitogens include 
serum, EGF,TGFa, PDGF, and bFGF (Linzer and Nathans, 1983; Nilsen-
Hamilton ef a/., 1988; Nilsen-Hamilton etaL, 1980). Nilsen-Hamilton and 
colleagues showed that, in quiescent 3T3 cells, 18 hours of treatment with EGF 
or TPA induced a 8 or 3 fold increase respectively in the amount of secreted 
metabolically-iabeled MRP/PLF (Nilsen-Hamilton et al., 1988). In growing cells. 
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growth factors also stimulate a similar fold increase in MRP/PLF expression, 
however, the basal level of expression is nearly 10 fold higher than that of 
quiescent cells, so the overall difference between quiescent untreated cells and 
growing, growth factor treated cells can be as high as 70 fold. This data 
demonstrated that expression increases in response to growth factors 
and the overall level of expression is dramatically affected by the growth state of 
the cell. 
Mrp/plfmRNA levels increase in response to mitogens (Nilsen-Hamilton eta!., 
1987) (Linzer and Nathans, 1984; Linzer and Wilder, 1987; Mohideen etal., 
1999). The increase in m/p/p/f expression in response to growth factors or serum 
correlates with entry into G1 of the cell cycle, and cells that have reached 
confluency express much lower levels of m/p/p/f (Linzer and Wilder, 1987). 
Further characterization of the increase in mrp/plfmRNA showed that 
cycloheximide treatment during stimulation prevented the growth factor-induced 
Increase in mrp/plf mRNA, suggesting that translation was necessary prior to 
upregulation of the message (Linzer and Wilder, 1987). Presumably, new 
transcription factors are being produced in response to mitogen stimulation, and 
these may be necessary to induce mrp^/f transcription. Analysis of the mrp/pff 
promoters for regulatory elements that may be involved in transcriptional 
regulation revealed a number of previously described transcriptional elements 
within the first 600 bp of the three separate promoters which have been 
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sequenced; these include a TATA box, AP2 site, GATA ^ ctor binding elements, 
AP1 sites, SPH elements, and a glucocorticoid response element. Deletion and 
mutation analysis of these promoters has revealed roles for a number of these 
elements in growth factor related activity. AP1 sites and three separate SPH 
sites located within -204 to -231 of the transcriptional start site are required for 
and have a synergistic effect upon promoter activity in response to serum 
(Groskopf and Linzer, 1994; Mordacq and Linzer, 1989). A composite 
glucocorticoid binding site located within this region has also been investigated. 
This site is able to depress serum induced promoter activity in transfected L-cells 
in response to dexamethasome through an interaction with the glucocorticoid 
receptor (Groskopf and Linzer, 1994; Mordacq and Linzer, 1989). Interestingly, 
repression through this element requires interaction with Fos and Jun 
transcription factors, but interaction with Jun alone has a positive effect upon 
activity (Diamond et a!., 1990). It has been suggested that the repression of 
mrp/p/f promoters by glucocorticoids coutel be related to the decrease in 
placental mrp/ptf expression during late gestation when higher levels of 
glucocorticoids accumulate (Mordacq and Linzer, 1989). 
Like the cDNAs which have been identified so far, the sequences of the 
mrp/p/f promoters that have been identified are *- 97% homologous with one 
another. Mohideen et. al used this homology, in combination with the results of 
studies of the ability of truncated mrp3 promoter fragments to respond to bFGF, 
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to identify a sequence involved in differences in bFGF responsiveness between 
the proximal 600 bps of the mrp3 and plf42 or plf149 promoters (Mohideen et a!., 
1999). They identified an element in the mrp3 promoter at -180 to -150 that 
differs by three base pairs from the site in plf42 and by 2 basepairs in plf149 and 
Is able to induce a 2-4 fold increase in reporter gene expression in response to 
FGF. This element is termed the FRE, and can also be found in a number of 
other growth factor induced genes, particulariy genes that encode secreted 
proteases (Mohideen et a/., 1999). When placed upstream of a minimal TK 
promoter, the FRE confers FGF responsiveness upon that gene. Furthermore, 
proteins from nuclear extracts of 3T3 cells, placenta and embryo, but not liver, 
bind the FRE, suggesting that these proteins and/or this element may play a role 
in regulating a number of genes expressed during development (Hruska A.; 
Thesis, 1998). These investigations identified a few of the elements in the 
mrp/plf promoters that are probably involved in the transcriptional regulation of 
these genes, and they show that there are functional growth factor-inducible 
elements within the promoters. Furthermore, they show that subtle 
differences in the sequences of these elements can lead to different responses 
to extemal stimuli. It would therefore be of interest in this regard, to determine 
how the different m/p/p/f promoters are regulated in vivo, so that the roles of the 
elements involved in mrp/p  ^promoter regulation could be given a physiological 
significance. 
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Post-transcriptional regulation of m/p/p^transcripts 
Despite the apparent transcriptional regulation of promoter/reporter gene 
constructs in transfected cells, a puzzling piece of evidence exists, which 
suggests that the increase in endogenous mrp/js/f expression in 3T3 cells in 
response to serum or growth factors is not due to an increase in transcription 
rate. Two separate groups have used nuclear run-off to measure transcription of 
mrp/pff genes in response to either serum or bFGF, but neither have detected an 
increase in the rate of transcription (Linzer and Wilder. 1987; Mohideen, 1995). 
Further analysis of the post-transcriptional regulation of the mrp/plf genes 
suggest that in unstimulated cells, the message is degraded in the nucleus, and 
it is suspected that an alteration in the ability to fully process the heterogenous 
RNA into mRNA is involved in the response to mitogens (Linzer and Wilder, 
1987; Mohideen, 1995). A similar method of gene regulation has been attributed 
to the repression of m/p/jD/f expression in mouse embryo fibroblasts before they 
become immortalized, at which point m/p/p/f expression begins (Edwards etal., 
1987; Malyankar ef a/., 1994; Malyankar ef a/., 1996). Nuclear post-transcriptioal 
regulation has also been descrit>ed for a number of other genes including 
fibronectin, dihydrofolate reductase, interieukin-2 and hemoglobin genes 
(Chandler ef a/., 1994; Gerezefa/., 1995; Kollia etal., 1996; Leysef a/., 1984). 
In the case of fibronectin, activated ras mediates a down regulation of fibronectin 
at the level of nuclear processing of the primary transcript, while 
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dexamethasome treatment increased fibronectin expression by stabilizing the 
primary transcript (Ehretsmann eta!., 1995). Dihydrofolate reductase and 
interieukin-2 mRNA levels were tx>th reduced due to inefficient processing of the 
primary transcripts in the absence of stimulation. The hemoglobin genes, which 
are developmentally regulated in eruthroid cells by transcriptional control, also 
appear to be regulated at the post-transcriptional level as incompletely spliced 
transcripts of e-globin are detectable in adult cell types, but the fully processed 
gene or protein is not detectable. Likewise, low levels of incompletely spliced p-
globin genes are detectable in cells that express primarily the embryonic forms. 
The mechanism by which growth factors or developmental signals regulate 
nuclear processing or nuclear stability of transcripts in these or other cases is still 
not well understood, and could occur more often than what is reported, as 
unprocessed primary transcripts would likely be degraded in the nucleus and 
may not accumulate to easily detectable levels. The lack of correlation between 
mitogen regulated promoter activity in reporter gene assays and endogenous 
transcription also needs to be resolved if the true mechanism of mrp/plf 
regulation Is to be understood. Because however, the promoter for each form of 
mrp/plf has not been identified, and t)ecause there are multiple mrp/plf genes, 
not distinguishable from one another by hybridization assays, evaluation of the 
precise mechanism of mrp/plf regulation may be complicated, particulariy if the 
different mrp/plf genes are being differently regulated (eg. transcriptionally vs. 
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post-transcriptionaliy) 
Regulation of mip/p/f expression in the placenta 
While the promoters oi mrp/plf genes have been Investigated In cell culture, 
little is known about how these promoters are regulated in vivo. In the mouse, 
expression of mrp/plf has only been shown in the trophoblastic giant cells 
(TGCs). In these cells, which begin to form during the blastocyst stage, cell 
division has ceased, but ONA synthesis continues in a process referred to as 
endoreplication (Zybina, 1970). Endoreplication continues up to day 14 (Jollie, 
1964). Interestingly, the period of highest level m/p /^f expression in the giant 
cells (e9-11) occurs at a time when TGCs are still forming and are found at high 
numbers (Bariow, 1972; Muntenerand Hsu, 1977; Zybina, 1970). So lil<e 3T3 
cells, there may be a correlation t)etween ONA synthesis and m/p/^ /f expression 
(Nilsen-Hamilton etal., 1980). Therefore, some of the elements involved in 
growth factor induced increases in mrp/plf expression are likely to be the same in 
giant cells and 3T3 cells. However, t>ecause the giant cells are difficult to Isolate 
and culture, the best way to identify elements of the m/p/^ /f promoters that are 
involved in giant cell regulation of mrp/^ /f expression is to produce transgenic 
mice using various mrp/J /^f promoter reporter gene constructs. This work has not 
been previously reported for the mrp/plf genes, but is carried out in the research 
described in this thesis. 
25 
A number of investigations have been carried out involving endogenous 
expression in the placenta in various conditions that give insight into how 
these genes are regulated in vivo. The most significant finding was provided by 
Ma et. al who show that placentae genetically null for functional QATA-3 and 
especially GATA-2 transcription factor genes produce much less MRP/PLF than 
heterozygous placentae from the same mating (Ma et al., 1997). This, along 
with in vitro evidence that GATA factors regulate activity of the closely related 
Mouse Placental Lactogen I promoter (Ng et al., 1994) suggest that these 
transcription factors play an important role in expression in vivo. Like the 
mPL I promoter, the promoters contain a number of GATA sites through 
which regulation may occur. JunB, a memtser of the AP-1 complex, which has 
been demonstrated to t)e important transcriptional response to serum 
stimulation, has also been shown to be essential for correct placental 
development, placental m/p/p/f expression, and neovascularization (Schorpp-
Kistner et al., 1999). Other studies have shown that cAMP treatment can 
increase the number of trophoblastic giant cells expressing mrp/plf in vitro 
(Yamaguchi et al., 1995). This is believed to occur however, by increasing the 
number of cells differentiating into giant cells, and may not be a result of 
increased level of expression in each giant cell. Studies involving mrp/plf 
expression in vitro have also been carried out on blastocyst outgrowths, in which 
giant cells were allowed to differentiate outside of the uterus. Here it was shown 
26 
that giant cells still progress through a similar order of expression of GH/PRL 
related genes including mrp/plf, suggesting that a major part of m/p/p/f regulation 
is the differentiation state of the cell (Carney et at., 1993). Another interesting 
aspect of regulation in giant cells is the down regulation of mrp/plf 
expression. In vivo, expression peaks between days 10 and 11 p.c. and 
then rapidly decreases. When removed from the uterus after day 11 however, 
and cultured in media, expression of MRP/PLF protein returns to high levels, 
suggesting that the uterus may play a role in down regulation of mrp/plf after e11 
(Fang et al., 1999). There is likely to be a uterine factor involved in MRP/PLF 
down-regulation, because co-culture in vitro of giant cells in placental minces 
with late stage uterus, but less so with early stage uterus, causes a specific 
decrease in secreted MRP/PLF similar to that seen in vivo. Also, late gestational 
uterine extracts specifically inhibit the production of MRP/PLF (Fang et al., 
1999). 
Other insight into tissue specific activity of the mrp/plf promoter could be 
gleaned from results of experiments involving other genes expressed in the 
trophoblastic giant cells. The Mouse Placental Lactogen II promoter is expressed 
specifically in transgenic placentae if 2 kb of promoter sequence was used, but 
was inactive if only 1.3 kb was used. Transient transfection of a rat trophoblast 
cell line (RCHO-1) was then used to identify two previously undescribed AT-rich 
elements that are necessary for high-level expression in giant cells (Lin and 
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Linzer, 1998). These elements have not however, been identified in the mrp/plf 
promoters. Analysis of the placental lactogen I promoter was carried out by 
transient transfection in RCHO-1 cells and it was shown that expression from this 
promoter is dependent on GATA binding sites in the promoter and transcription 
is increased by exogenous expression of GATA factors 2 and 3 (Ng et al.. 1994). 
Like the mPL I promoter, the Murine Adenosine Deaminase promoter (ADA) is 
also regulated by GATA Actors. This gene is not a memt>er of the GH/PRL 
family, but is expressed strongly in the placenta in all trophoblast lineages. 
Placental specific expression of ADA/cat transgenes depended on a 770 bp 
region located 5.4 kb from the transcriptional start site. This region contained 
multiple placental-specific footprints as well as footprints produced by non-
placental tissues. Furthermore, this region contained a number of previously 
described elements involved in placenta specific expression, including GATA 
elements. In this case, mutation of two GATA elements within the 770 bp region 
in the ADA promoter decreased the level of expression but did not drastically 
effect tissue specificity of expression of reporter gene activity (Shi et al., 1997). 
Other elements were also found to be involved in placenta specific expression. 
Deletion of a region containing homology to the human placental lactogen 
enhancer completely diminished CAT reporter gene expression, even though it 
did not contain a footprint, as did a separate region that did produce a placenta 
specific footprint. This placenta-specific footprint contained a binding site for AP-
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2 that is enriched in trophobiast lineages, and mutation of this site abolished 
placenta specific expression (Shi and Kellems, 1998). The mrp/plf promoters 
also contain an AP-2 site in the proximal promoter. Another region that 
produced footprints in both placenta and liver was also found to be necessary for 
placenta-specific expression (Shi et aL, 1997). These data suggest that GATA 
factors may play a role in placenta-specific expression, but other factors, both 
tissue specific and othen/vise, are also involved, and like many enhancers and 
promoters, tissue specific expression is the result of an interplay between 
multiple elements. 
One particulariy well investigated example of how tissue specific gene 
expression may be mediated by surrounding sequences is the regulation of the 
pituitary specific human growth hormone gene (hGH) and it's closely related 
placenta specific family members. The GH gene is found in a cluster of five 
genes that are 93-96% similar in sequence identity in the proximal 5' flanking 
region and coding sequences (Miller and Et>erhardt, 1983), but are expressed in 
distinct patterns. While hGH-N is only expressed at high levels in the anterior 
pituitary, hCS-A and B are strongly expressed only in the placenta, where the 
other two (hGh-V and hCS-L) are also expressed but at a weaker level. This 
system can therefore provide insight into how different tissue specific expression 
patterns are established even amongst genes that are highly similar. 
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Analysis of the promoter activity of hGH and hCS genes in transfected cells 
has revealed some differences in the proximal 5' or 3' flanking regions which 
effect pituitary or placental cell specific expression. For instance, the 0.5 kb 5' 
flanking regions of the hCS-A and hGH-N genes are both active in pituitary cell 
lines (Cattini and Et)erhardt. 1987; Cattini etal.. 1988; Nachtigal etal., 1989) and 
bind Pit-1 (Bodner 1987, Lefevre 1987) transcription factor, even though only 
hGH-N is expressed in the pituitary in vivo. The high level expression of pit-1 in 
the pituitary, and the ability of pit-1 to transactivate the hGH promoter in extracts 
of non-pituitary cells (Bodner and Karin, 1987) suggests that pituitary specfic 
hGH promoter requires expression and activity of Pit-1. Furthermore, mutation of 
Pit-1 is a known cause of pituitary dwarfism, demonstrating the Important 
contribution of Pit-1 to growth hormone expression ( Frisch, 2000). The activity of 
the 0.5 kb hCS-A promoter in pituitary derived ceils however, suggests that other 
sequences may be necessary for repression of hCS genes in the pituitary. In 
support of this, two specific "PSF" sequences within 1.7 to 2.1 kb 5' of each of 
the hCS genes can severely repress pituitary specific expression. These 
elements bind nuclear proteins from pituitary cell lines, but do not repress 
expression in placental cell lines or bind similar placental proteins ( Nachtigal et. 
al., 1993). The promoters for hCS-A and hGH-N appear to be in an "open" 
chromatin state in the pituitary (Nickel and Cattini, 1996), suggesting that the 
promoters are both accessible to trans-activating factors. It is therefore possible 
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that these hCS specific sequences nnay be involved in pituitary specific 
repression of placental GH genes (Nickel and Cattini) which is not mediated by 
chromatin mediated inaccessibility. The mechanism by which these repressors 
prevent expression of the hCS genes however, remains undetermined. There is 
also an enhancer described in the 3' end of the hCS-B gene which functions only 
in placental cell lines and may also contribute to placental specific activation of 
the hCS genes.(Jacquemin eta!., 1994; Rogers etai, 1986). This enhancer 
binds specific proteins in the placenta, which are different from proteins bound in 
pituitary cells, where it also contributes to repression of hCS gene expression 
(Jiang and Eberhardt, 1997). Thus, while very proximal sequences (0.5 kb) are 
similar In sequence and activity, more distal sequences in the 5' and 3' flanking 
sequences and the proteins which bind there override the influence of the very 
proximal sequences to promote tissue specific transcription. Another level of 
regulation also exists in vivo however. 
The experiments described above, carried out in for the most part in 
transiently transfected cell lines, may not adequately represent what occurs in 
vivo, particularly in the context of chromatin structure and development. For 
instance, even though the proximal 5' region (0.5 to 5kb) of the human growth 
hormone (hGH-N) promoter, is regulated by pit-1, in transfected pituitary cell 
lines (Bodner, 1988; Fox eta!., 1990; Sittler and Reudelhuber, 1990), it is not 
expressed or is expressed at low and variable levels in the pituitaries of 
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transgenic mice (Bennani-Barti etaL, 1998) (Hammer RE, 1984; Jones eta!., 
1995). Also, a 15kb fragment containing 5kb of 5' and 7kb of 3' sequence of the 
hCS-A gene was poorly and variably expressed in the placentae of transgenics, 
suggesting that further elements are required for appropriate tissue specific 
expression of these genes. Indeed, it is now evident that high level, tissue 
specific and site-of-integration-independent expression of the hGH-N gene in 
pituitaries and placentae of transgenic mice depends on 4 ONAse hypersensitive 
sites (HS) between 14 and and 40 kb 5' of the hGH-N gene (Bennani-Baiti et al., 
1998; Jones et a/., 1995). Two of these sites (HS I and II) are specific for the 
pituitary, while two other HS sites (HS iii and V) are found in both the placenta 
and the pituitary, and another HS site (HS IV) is found in only the placenta. The 
two most proximal pituitary specific HS sites at-14.6 and -15.4 (I and II) in their 
natural context or when isolated and linked to 0.5kb of the hGH promoter result 
in high level position independent transgene expression, but also allow slight 
ectopic expression of the transgene. Expression levels from the 0.5 kb hGH 
promoter were on average 1000 fold higher with addition of the HS I and II 
fragment than in it's absence. The two HS sites at -32.5 and -27.5 (HS III and 
V) also allow position independent transgene expression when attached as an 
11.5 kb fragment to the 0.5 kb promoter, but expression levels are much lower 
than transgenes containing sites I and II. Again, ectopic expression is observed, 
this time consistently in the kidney. Here it is important to note that p/M is also 
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expressed in the Icidney, suggesting that distal HS sites are necessary to allow 
p/M activity on the proximal O.Skb promoter, but other sequences removed from 
this construct are required to repress this activity. Only the complete 40kb 
fragment containing all four HS sites allowed tissue specific and position 
independent transgene expression. Recently it has been demonstrated that the 
HS I and II sites in the hGH 5' region, which were specific for the pituitary, are 
dependent upon PIT-I for activity (shewchuk 1999), demonstrating that the 
transcription factor PiT-1 plays an important role in the proximal promoter activity 
during transient transfection, as well as in distal sites which overcome inhibition 
by surrounding chromatin. Consistent with a role of LCRs in overcoming 
inhibitory chromatin structure is the finding that the hGH-N locus control region is 
a target for histone acetyl transferase activity in the pituitary that results in 
increased acetylation that spreads into the hOH-N gene, but does not extend into 
the placental genes (Elefant etal., 2000). Interestingly, transgenic mice 
containing the 40kb 5' region and ail five genes of the hGH locus also express 
the human placental specific members of the locus at high levels in the 
placentae of transgenic mice.(Su etal., 2000), even though the placental 
members of the PRL/GH super family in rodents are derived from Prolactin. The 
complex regulation of the hGH gene cluster demonstrates the importance of both 
proximal promoter elements that can bind tissue specific transcriptional 
activators or repressors, and other possibly distant elements that are likely 
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involved in overcoming inhibitory chromatin structure. 
Post-translational regulation of MRP/PLF 
The MRP/PLFs are expressed from 3T3 cells as 34kd glycoproteins (Nilsen-
Hamilton et al., 1980). In the placenta, the MRP/PLFs are found as 27, 34. and 
38 kd forms, but the amino acid sequence predicts a 22 kd protein. These 
differences may be due to differential glycosylation states for specific MRP/PLFs, 
or to different levels of glycosylation on the same protein. Interestingly, the 
pattern of expression of these different molecular weight MRP/PLF species 
changes during gestation. While the higher molecular weight form (38kd) is 
expressed in early and midgestation, the 27kd form is expressed strongest on 
day 13 (Fang et al., 1999). The 27 kd form is only found in the placenta however, 
and not in the amniotic fluid or the matemal serum. This suggests that the 27 kd 
forni is either not released into the bloodstream, is taken up rapidly by placental 
or decidual receptors, or is very unstable in the blood. The significance of 
different glycosylation states of MRP/PLFs has not been determined, but it could 
be envisioned that the level and type of glycosylation could correlate positively 
with the solubility or stability of MRP/PLF as it does for a number of proteins 
(Joannou, 1998; Melikian, 1996; Wang. 1996). including mPLI and 2 (Kelly. 
1975). Alternatively the glycosylation state could effect the interaction of MRP 
with a receptor. The glycosylation state could be especially relevent to 
interactions with the mannose-6 phosphate receptor, but at this time it is not 
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known which glycosylation site on MRP/PLF contains the mannose-6 phosphate 
residues that are involved in receptor binding. 
In conclusion, the MRP/PLFs are growth factors and angiogenesis factors that 
are expressed by the mouse placenta and also expressed in immortalized 
mouse cell lines. The cDNAs of three out of four to six of the mrp/plf genes have 
been identified, and three separate but highly homologous promoters 
have been studied in transfected cells. The mrp l^f promoters are regulated 
differently in response to various stimuli, and transcriptional differenceshave 
been identified that are involved in mediating these differences. The 
physiological relevence of these differences in promoter regulation 
however, remain unknown. While it has t>een shown that the mrp/plfs are 
expressed by the trophoblastic giant cells and that expression peaks during mid-
gestation, there are many questions remaining in regards to in vivo mrp/plf 
regulation. For example; What is the significance of multiple mrp/plf ger^es? 
Which mrp/plfs are the most prevalent in the placenta? Are they all expressed in 
the placenta at the same time, or might they tie regulated differently from 
another in vivo, as the identified promoters are in vitro? Furthermore, what are 
the transcriptional elements that drive high levels of giant cell mrp/plf 
expression? This latter question cannot be answered until it is known which 
mrp/plfs are expressed in the placenta, so that the appropriate promoter may be 
analyzed. 
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Another question that remains is whether or not mrp/plf\s really expressed 
only in the giant cells? This is an important question to ask if one is to form a 
hypothesis to explain tissue-specific expression of mrp/plf. In the study by 
Linzer, in which the placenta was identified as the site of mrp/p^synthesis, the 
only other adult tissues examined were the liver, kidney, brain, and ovaries 
(Linzer et al., 1985). These organs do not contain a large number of proliferating 
cells. Because of the strong correlation between expression, mitogen 
stimulation, and DNA synthesis (Nilsen-Hamilton etai, 1980), it is possible that 
there are other sites in the adult mouse that contain cells proliferating in 
response to growth factors and where mrp/plf may be expressed. 
Another question regarding tissue specific expression of the mrp/plf genes is 
based on the observation that the increases in endogenous m/p/jD/f expression 
levels in cultured cells do not appear to be transcriptionally regulated, but are 
regulated by a mechanism involved in processing of the primary transcript 
(Linzer and Wilder, 1987; Mohideen, 1995). Because this observation also 
applies to primary cultures of mouse embryo fibroblasts (Malyankar et a!., 1994; 
Malyankar et al., 1996), it is possible that the promoters may t}e active in 
the intact mouse embryo as well, or even in the aduK mouse, but that the 
message is not detected because of post-transcriptional degradation. Do 
trophoblastic giant cells increase mrp/plf expression by increasing the rate of 
transcription of the gene or is the mechanism of regulation post-transcriptional? 
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Perhaps the massive tissue specific increase in expression is a result of 
a combination of transcriptional and post-transcriptional regulation. This leaves 
open the question of what to expect when analyzing the activity of the mrp/plf 
promoters in vivo. If tissue specificity is solely under the control of the mrp/plf 
promoter, then tissue specific expression of a reporter gene under control of a 
transgenic mrp/plf promoter might be expected. If promoter activity is 
constitutive however, as the endogenous promoter for p/fl appears to be in 3T3 
cells, and post transcriptional regulation occurs at the level of the primary 
transcript, then a reporter gene may not be similarily post transcriptionally 
regulated. In this case, transgene expression would appear non-specific, and 
further investigation into post-transcriptional processing of the mrp3 gene would 
be necessary. Answering these questions regarding the expression patterns of 
multiple mrp/plf forms, and the activity of the mrp/p  ^promoters in vivo is crucial 
to our understanding of the function and regulation this gene family, and is 
therefore, the goal of the research described in this thesis. 
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CHAPTER 3: MRP4. A NEW MITOGEN-REGULATED 
PROTEIN/PROLIFERIN GENE; UNIQUE IN THIS GENE FAMILY FOR ITS 
EXPRESSION IN THE ADULT MOUSE TAIL AND EAR 
A paper published in ENDOCRINOLOGY 
J. T. Fassett\ R. T. Hamilton\ and M. Nilsen-Hamilton^"  ^
ABSTRACT 
Mitogen-regulated proteins (also known as proliferin;N7/7V^/0 are 
nonclassical members of the PRLyGH family. They are expressed at high levels 
during midgestation when they are thought to induce angiogenesis and uterine 
growth. There are between four and six mrp/plf genes, and three different cDNAs 
have been cloned. Here we identify a fourth mrp/plf gene (mrp4) that we have 
cloned and characterized. MRP4 is 91% identical in amino acid sequence with 
the other MRP/PLF proteins but is missing two glycosylation sites that are 
present in the other forms. Consistent with the loss of two of three glycosylation 
sites, the expressed form of MRP4 has a lower apparent molecular weight 
Departments of ^Zoology and Genetics and ^ Biochemistry, Biophysics and 
Molecular Biology, Iowa State University, Ames, Iowa 
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compared to other MRP/PLFs. In vivo, mrp4 is expressed in the placenta and 
the adult skin. Expression of mrp4 mRNA peaks in the placenta on day 12. In 
the skin, mrp4 expression is specific to the ears and tails of mice. Our results 
suggest that, as well as having growth and angiogenic effects during pregnancy, 
the MRP/PLFs may have functions in nonreproductive tissues. Unique amongst 
the members of the family for its expression in the hair follicles of the tail 
and ear, MRP4 is expected to have a singular role in the growth and 
development of these follicles. 
INTRODUCTION 
Proteins of the prolactin/growth hormone (PRUGH) family play essential 
roles in growth and reproduction in mammals. Humans contain three placenta-
specific variants of hGH (1) while rodents have evolved numerous placental-
expressed descendents of prolactin (2). In the mouse, the placental memt)ers 
of the family include placental lactogens I and II (mPLs) (3-5), proliferin-related 
protein (PRP) (6); the more recently identified homologues of the rat prolactin-
llke proteins (PLP A,B,Ca, Cv, E through L, and d/t-PRP) (7-12), and the mitogen 
regulated proteins (proliferins; MRP/PLF) (13). MRP/PLFs are glycoproteins 
consisting of a polypeptide core of 21 kOa and appear by gel electrophoresis to 
be of average sizes varying from 27K to 38K. Like some other members of the 
PRL/GH family, the MRP/PLFs are synthesized in the placenta and their 
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synthesis is temporally regulated during gestation (6. 14). Expression of the 
mrp/plf genes in the placenta begins as early as E7, peaks at midgestation (E9-
11), then declines through the remainder of gestation. In situ hybridization and 
immunohistochemistry have kientified the trophoblastic giant cells as the site of 
MRP/PLF synthesis in the placenta, from which it is released into both the 
matemal bloodstream and the amniotic fluid (15). MRP/PLFs are believed to 
function during pregnancy as placental angiogenesis factors through their 
interaction with the mannose-6-phosphate receptor (16) and as uterine growth 
factors through another receptor that is specific for MRP/PLFs and does not 
recognize mannose-6-phosphate (17). PLF1 also has been described as having 
an intracellular role, in preventing muscle differentiation (18, 19). 
The mouse genome contains between four and six mrp/plf genes (20) and 
previous to this report, three cONAs had t>een cloned: pifl from serum-
stimulated 3T3 cells (21), plf2 from a Balb/c mouse placental cDNA library (22). 
and mrp3 from a Swiss mouse embryo fibroblast library (23). The three 
MRP/PLFs are -98% identical in amino acid sequence and the variations in 
sequence do not disrupt any predicted structural motifs. Thus it is likely that all 
three previously identified MRP/PLFs have a similar structure. Each of the 
identified MRP/PLFs contain three N-glycosylation motifs within the sequence of 
the mature secreted protein, and all placental and 3T3 forms are glycosylated 
(13, 22, 24). Because MRP/PLF binds at least two different receptors during 
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gestation, only one of which recognizes mannose-6-phosphate. the level of 
glycosylation could be important in determining the functional interactions of the 
MRP/PLFs with their receptors in vivo (16, 17, 25). 
Here we describe a fourth mrp/plfmRhIA {mrp4) that we have cloned, 
sequenced and characterized. The mature protein produced from this newly 
discovered memt>er of the m/p /^fjgene family is 91% identical in amino acid 
sequence to the other memtiers of the family. MRP4 lacks two of the three 
glycosylation sites found on the other MRP/PLFs. and when expressed, it 
appears to contain less carbohydrate than the other MRP/PLFs. Expression of 
mrp4 mRNA is consistent with the presence of MRP/PLF protein found in the 
placenta in the latter half of gestation and that has a lower apparent molecular 
weight than the plasma form of MRP/PLFs. MRP4 is also the only mrp/plfmRHfK 
species detected in hair follicles of the tail and the ears of adult mice. These 
results suggest that, as well as functioning to stimulate uterine growth and 
placental vascularization during pregnancy, the MRP/PLFs also may have a 
specific function in adult hair follicles. Because mrp4 is the only member of the 
mrp/p/f gene family expressed in the tail and the ear, this gene may play a 
singular role in these tissues. 
MATERIALS AND METHODS 
Animals and materials CF-1 and FVB mice, originally obtained from 
Charles River (Wilmington, MA), were bred and cared for at the Laboratory 
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Animal Facility at Iowa State University under a 12-h light/dark cycle. For 
pregnant animals, the day of the plug was counted as day 0. Animal care was 
provided by an animal caretaker and an attending veterinarian. This research 
was conducted in accordance with the standards set forth in the NIH guide for 
the care and use of laboratory animals. Animals were killed by cervical 
dislocation prior to removal of tissues for the descrit)ed studies. Prior approval 
was obtained from the Iowa State University Committee on Animal Care for all 
procedures performed on the animals used in these studies. 
Polyclonal anti-MRP rabbit sera and preimmune sera were prepared as 
described (26). pRSV-plf1 and pRSV-plf2 plasmids and a set of cosmids 
containing m/p/p/f-hybridizing sequences were gifts from Jiandie Lin and Daniel 
Linzer (Northwestern University). The pBluescript II KS^" '^ plasmid (pSKSIK) was 
obtained from Stratagene (La Jolla, CA), and the pcONA3 expression vector 
was obtained from Invitrogen (Carisbad, CA). The full mrp3 gene extending from 
-1450 to 600 bp past the poly A site (including introns) was obtained from David 
Denhardt (Rutgers University) in four separate pieces. The full-length genomic 
clone from -1450 was reconstructed almost completely except for an 
approximately 230 basepair Accl-Pvull fragment of intron I and a 300 basepair 
EcoRI fragment of intron 3, which were removed during cloning. The 
reconstructed gene was placed downstream of the CMV (cytomegalovirus) 
enhancer (obtained from pcDNA3) to produce pCMV-MRP3. Tunicamycin was 
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from Sigma (St. Louis, MO). Dulbecco-Vogt's modified Eagles medium with high 
glucose (DMEG) was from Gibco BRL. 
RNA isolation and RT-PCR Immediately after their removal, tissues were 
frozen under liquid nitrogen and stored at -70 C until use. Frozen tissue was 
pulverized in liquid nitrogen using a mortar and pestle, and RNA was isolated 
using Tri-Reagent (Gibco BRL) according to the manufacturer's instructions. For 
reverse transcription, 250 ng of total RNA was incubated with or without 40 units 
of Superscript II reverse transcriptase (Gibco BRL) in 5-^1 reaction mixtures 
containing 75 mM KCI, 3 mM MgClz, 10 mM DTT, 112 ng poly dT primers, 
400 iiM each of the four dNTPs (dATP, dGTP, dCTP, dTTP), and 50 mM 
Tris-HCI (pH 8.3 at RT). The reaction mixtures were incubated at 42 C for 50 
min, 50 C for 10 min, then 75 C for 15 min. 
For PCR, the following primers were used; downstream exon 1 
(DEI), 5TAAGCCTGGGTAGGACTCTGC3' (+45 to +65), or (DE1B) 
5'CTCTGCAGAGATGCTCCCTTC3' (+59 to +79) and upstream exon V (NUE5), 
5'CATGATATTTCAGAAGCAGAGCAC3' (+778 to +756). Briefly, 0.5 ^ il of the reverse 
transcription reaction mix was added to a 25-^1 volume containing 1 unit of Taq 
Polymerase, 20 pmoles of each primer, 200 nM of each of the four dNTPs, 
1.5 mM MgCb, 50 mM KCI, and 10 mM Tris-HCI (pH 8.3). The thermal cycling 
conditions were as follows: 95 C for 2 min to denature, then 40 cycles at 95 C 
(30 sec), 66 C (1 min), and 72 C (1.5 min) with a final 3 min at 72 C. The PCR 
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products were resolved by electrophoresis through a 1.5 % agarose gel and 
examined by ethidium bromide staining. 
Diagnostic restriction digestion to distinguish between the mrp/plf 
mRNA The diagnostic RT-PCR assay for the mrp/plfs is based on minor 
differences in the cDNA sequences of these closely related gene products which 
result in the presence or absence of restriction sites within the cDNA that can be 
used to distinguish between the mqo/plfmRNAs (Fig. 1). For restriction 
digestion, one-fifth of the reaction mixture from the RT-PCR reaction was 
subjected to one additional round of PGR using DE1B and NUE5 primers and 
62.5 nM of each of the four dNTPs, 0.9 mM MgCb and 1 nCi ^ P-adCTP in a 25-
nl volume. The sample was heated to 98 C for 4 min, 64 C for 1 min, then 72 C 
for 20 min. The radiolabelled cDNA was precipitated with 70% ethanol in the 
presence of 0.3 M sodium acetate with 10 fig yeast tRNA as a cam'er. Digestion 
was carried out using 1 unit each of BsoFI (New England Biolabs, Beverly. MA) 
and BstXI at 55 C overnight, or 5 units of Ndel (Gibco BRL; Roclcville, MO) at 
37 C including 100 ^ g/ml bovine serum albumin (New England Biolabs. Beverly, 
MA). The radiolabeled and digested products were resolved by electrophoresis 
through a 2% agarose gel or an 8% or 10% polyacrylamide gel. The gel was 
dried, and the amount of radioactivity associated with each band was determined 
using a phosphorimager and ImageQuant software (Molecular Dynamics, 
Sunnyvale, CA). Positive controls for identification of specific mrp/plf cDHAs 
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were amplified from pRSV-plf1 or pRSV-plf2 cDNAs, or were produced using 
mRNA isolated from COS cells that had t)een transiently transfected with pCMV-
MRP3. The diagnostic RT-PCR was validated using known mixes of mrp/ptf 
cDNAs followed by amplification and diagnostic RT-PCR. The amount of each 
cDNA was then determined quantitatively after restriction digestion and found to 
reflect the expected ratio of each cDNA. 
Other mrp/ptf ^nmexs used for RT-PCR In these studies were: DAP1 (-230 
with the addition of CCAC at the 5' end; 5'CCACTAGTCAGAGCATGAACAT3') and 
M3V55 (-129; with the addition of CCACTAG at the 5' end 
S'CCACTAGTCATGGTATCTAGGCTACTTS') 
Cloning and sequencing of the mrp4 cDNA The mrp4 cDNA was cloned 
from day 13 CF-1 mouse placenta. Total placental RNA was isolated and 
reverse transcribed as described under RNA isolation and RT-PCR. The 
fragment was amplified by PCR using the following primers: DE1; 
5'TAAGCCTGGGTAGGACTCTGC3' (+45 to +65). ZMRPUE5; 
5'GAAAAGGTTGTCAACAACAAATTCAAAAG3' (+820 to +801). Twenty-seven cycles of 
95 C (30 sec), 64 C (1 min) and 72 C (1.5 min) were performed using a low error 
rate amplification kit (Expand High Fidelity PCR System, Boehringer Mannheim. 
Indianapolis. IN). The PCR product was precipitated with ethanol, then digested 
5' and 3' of the coding regions using PstI and Hindi restriction endonucleases 
respectively. The resulting cDNA fragment was ligated into pBKSII+ that had 
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been cut with these same restriction endonucleases. The plasmid pBKS-nirp4 
was sequenced by the DNA Synthesis and Sequencing Facility at Iowa State 
University to verify the sequence of the n7/p4 cDNA insert. Two of the clones 
were sequenced. Because the two sequences differed in sequence at five base 
positions, total nnRNA isolated from two different tail samples were amplified by 
RT-PCR and the amplicons sequenced. The resulting sequences matched each 
other and clone 2 with the exception of a single base at position 221 in clone 2 
which was A. The base in this position in the two amplified total tail RNA 
samples was G, which matched that of the other three cloned mrp/plfs. The 
base at position 221 was therefore taken to be G because the amplified tail 
mRNA sequences were the sum of sequences of many mRNAs in each sample 
whereas the cDNA clone 2 was the result of a single copy of one mRNA. 
Expression of MRP4 in COS ceils The mrp4 cDNA was subcloned into 
pcDNA3 by digestion of pBKS-mrp4 with Smal and Xhol and insertion of the 
mrp4 cDNA into the blunt-ended Hindlll and Xhol sites of pcDNA3 to make 
pcONA3-mrp4. pcONAS-Plfl was made by cloning the Hindlll/Xbal fragment of 
pRSV-Plf 1 into the same sites in pcDNAS. COS cells were transiently 
transfected with pcDNA3-MRP4 or pcDNA3-PLF1 using DEAE-Dextran as co-
precipitant (27). After transfection, the cells were grown in DMEG 10% calf 
serum for 48 h, then switched to 2% calf serum with or without 5 ^ g/ml 
tunicamycin for 24 h. The culture medium was collected and spun in a 
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microcentrifuge for 1 min and then stored at 4 C. The cells were scraped Into 
lysis buffer (0.5% NP40.100 U/ml Trasylol. 10 ® M PMSF. 20 mM HEPES. pH 
7.25) and stored frozen at -70 C. 
Western blot analysis Tissue homogenates for Western blot analysis 
were prepared as follows: halves of two or more placentae from pregnant mice 
were collected on either day 11 or day 14 of gestation, pooled according to day 
of gestation and homogenized in the same lysis buffer used for cultured cells 
above. Large tissue debris were spun out, and the supematants were saved. 
Transfected COS cell lysates or homogenates from day 11 or day 14 placentae 
were separated on a 15% polyacrylamide-SDS gel as descrit>ed previously (28). 
The proteins were electroblotted to nitrocellulose membranes (Nitrobind; Micron 
Separations, Inc., Westborough, MA), and the MRP/PLFs were detected using 
rabbit anti-MRP/PLF antiserum at a dilution of 1/200, followed by treatment with 
horseradish peroxidase-conjugated protein A (Sigma) and Western blotting 
detection reagents (Amersham International, Buckingshire, England). 
Immunohistocemistry Tissues were fixed in 4% paraformaldehyde in PBS 
(0.14 M NaCI, 2.7 mM KCI, 4 mM Na2HP04, 14.7 mM KH2PO4. pH 7.4) for 1-2 h 
at 4°C immediately after collection. Samples were then rinsed in PBS and 
stored in 70% ethanol until sectioned. For immunodetection of MRP, 6 ^ m 
sections were rehydrated and stained as previously described (29) using a 
polyclonal rabbit anti-MRP/PLF serum (89rb13a) or a pre-immune serum from 
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the same animal, each at a dilution of 1/500. Primary antibody was detected 
using biotinylated goat anti-rabbit and horse radish peroxidase conjugated to 
avidin, and visualized by a peroxidase substrate, diamino t)enzidine 
tetrahydrochloride (ABC kit; Vectastain;Burlingame, CA). Samples were counter-
stained with hematoxylin and eosin, dehydrated, and mounted with permount 
(Fisher Scientific, Pittsburg PA) with a coverslip on top. 
Identification of the promotere for the different imp/p/f genes Cosmid 
clones containing m/p/jD/f-hybridizing sequences and a reconstructed mrp3 gene 
from -1450 to +600 basebairs past the poly A site and genomic DNA were 
amplified using primers that recognize the sequence from -(-dlO to +335 (exon 3; 
5'ACAAAAGCCCCATGAGATGCAATAC3') and from +455 to +435 (exon 4; 
5'ACTCACTAGATCGTCCAGAGG3'). PCR-amplified fragments were digested with 
EcoRI for 4 h at 37 C and then digested with either BsoFI or BstXI as described 
for diagnostic RT-PCR. The fragments were resolved through a 2% agarose gel. 
Individual clones that produced diagnostic PGR digestion pattems consistent 
with a particular m/p/p^cDNA were sequenced across the promoter region using 
a primer +71 to +43 (UE1; 5'CATCTCTGCAGAGTCCTACCCAGGCTTAG3' ) that 
hybridizes with the 5' end of mrp4 and the three mrp/plfs identified previous to 
this report (21-23). 
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RESULTS 
A new mrp/p/f mRNA that is expressed in the midgestationai placenta 
Because the placenta was previously the only tissue in which mrp/plf 
expression was observed, we used the diagnostic RT-PCR protocol diagramed 
in Fig. 1 to determine the relative proportions of mrp/plf mRHAs expressed in the 
placenta. By incorporating ^ PaCTP into the final round of amplification we were 
able to quantitatively determine, using a phosphorimager, the amount of each 
restriction fragment. The major form of m/p/p/f expressed during gestation was 
mrp3. This can be seen visually in Fig. 1 in which the majority of the radioactivity 
is associated with the 289 and 246 fragments that are diagnostic for mrp3. Less 
radioactivity was associated with the 318 bp fragment that is diagnostic for pl1 
and no radioactivity was associated with the 275 bp fragment diagnostic for plf2. 
However, we also found a form of mrp/plf mRtiA that was not digested at the 
internal BsoF1 and BstX1 sites present in the three cloned mrp/pHs. The 
undigested form of mrp/plf was found in the placenta at lower levels before day 
11 and peaks between days 12 and 14 (Fig. 1) (14). These results suggested 
the presence of a fourth, previously unidentified, mrp/plf mRt4A that is expressed 
in the placenta during late gestation that does not contain the intemal BsoFI or 
BstXI sites present in the three previously cloned mrp/plfs. 
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Cloning of mrp4 
The fourth mqj/plfcDHA that was identified as uncut by the diagnostic RT-
PCR procedure was cloned from day 13 placental RNA and sequenced as 
described in Materials and Methods to reveal a previously unknown mrp/plf 
cDNA {mrp4) with 91% amino acid identity to pifl (Fig. 2). Two noteworthy 
differences between mrp4 and the other three mqj/pffs are changes in amino 
acids 77 (Ser to Pro) and 88 (Asp to His) that would disrupt two of the three 
putative N-glycosylation sites found on the other three MRP/PLF mature protein 
sequences. 
Other possibly significant alterations include a stretch of five amino acids 
from 103 to 107 in which there are four differences between MRP4 and PLF1. 
Also, there is an in-frame deletion of two amino acids 167 and 168. Secondary 
structure analysis by NNPREDICT query (30) predicts that the substitutions in 
MRP4 at positions 186 and 188 result in the loss of helical tendency in the four 
alpha carbons between 185 and 188. 
Mrp4 expression in the placenta 
Among the nucleotide sequence differences between the mrp/pHs is the 
presence of a Nde I site at +649 that is unique to mrp4. To obtain further 
evidence that the /n/p4 gene accounts for the uncut portion of cDNA observed 
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during later gestation, rather than a different mrp/plf that also lacks the 
Bsofl/Bstxl sites, diagnostic RT-PCR was carried out on placental RNAs using 
Ndel in place of BsofI and BstxI. Measured in this way, mrp4 is found at higher 
relative levels on days 13-15 than days 9-11 of gestation as was shown 
previously with the Bsofl/Bstxl cleavage (Fig. 1) (14). Thus, both diagnostic RT-
PCR methods identify the same gene product, mip4, as having a different 
expression pattern relative to p/f1 and mrp3. 
Measurements of the relative amounts of plf1, mrp3 and mrp4 in the 
placenta as a function of gestation showed that the proportion of mrp3 varied 
between about 50% and 75% of the total mRNA throughout gestation. 
The relative amounts of plf1 and mrp4 varied reciprocally (Fig. 3). The maximum 
proportion of mrp4 was reached on day 12 when it constituted about 40% of the 
mrp/p/f vnRNA in the placenta. At this time, the proportion of ptf1 is at its lowest 
of about 13% from a high of about 35% on day 7 of gestation. 
MRP4 is glycosylated differently from PLF1 
To determine how the loss of two potential N-glycosylation sites affects the 
glycosylation of MRP4, COS cells were transiently transfected with pcDNA3-
MRP4 or pcDNA3-PLF1. Culture media and lysates of the transfected cells were 
analyzed by Westem blot and compared with the MRP/PLFs found in placental 
homogenates (Fig. 4). As expected, PLF1 migrated with an apparent molecular 
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weight ranging between 32K and 36K (13). By comparison, placental minces 
secrete MRP/PLFs of 27 kDa and 38 kDa. The 38-kDa MRP/PLF band was 
previously identified as containing MRP3 and PLF1 (14). MRP4 migrated at the 
same rate as the 27-kDa placental MRP/PLF. The 27-kDa MRP/PLF has a time 
course of appearance in gestation similar to that of the mrp4 mRNA. 
PLF1 and MRP4 are polypeptides having the same apparent molecular 
weight. This is demonstrated by a comparison of the nonglycosylated forms of 
the two proteins (Fig. 4). The nonglycosylated forms of the MRP/PLFs. 
produced by transfected cells that were incubated with tunicamycin, migrated as 
expected for the 21K molecular weight proteins predicted from their cDNA 
sequences. These results demonstrate that the difference in electrophoretic 
migration rates between the two MRP/PLFs is due to their glycosylation. Thus, 
the loss of two glycosylation sites in the MRP4 sequence results in the addition 
of less carbohydrate to this protein compared with PLF1. The placental MRP 
with the same apparent size as the recombinant MRP4 produced by COS cells is 
more predominant in day 14 placental lysates than day 11 lysates. This is 
consistent with the delayed expression of MRP4 mRNA relative to PLF1 and 
MRP3 in the placenta (Fig. 3) (14). 
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Differential cell and tissue-specific expression of mip/p/f genes. 
Although mqj/pHs were initially demonstrated by Northem blot analysis to be 
expressed only in the placenta (6), we show here that the mrp/ptfs are 
differentially expressed in a variety of mouse tissues (Fig. 5). Mrp/plfmRNAs 
were detected in the small intestine and tail but not in the liver, lungs, backskin, 
adult ribs or large intestine. The same expression pattern was found in males 
and females. Mrp/plfs were detected in some, but not all, stomach samples and 
at low levels in some samples of backskin (data not shown). Mrp/plk were also 
detected in 3T3 cells as expected from previous studies (13). The major mrp/plf 
expressed by 3T3 cells is plf1 consistent with the cloning of this mrp/ptfitam 
these cells (21). Samples incubated without reverse transcriptase showed no 
visible bands (Fig. 5A). Restriction analysis of radiolabeled cDNAs showed that 
the mouse tail produces only m/p4, while the small intestine and 3T3 cells 
produce mostly pifl with lower levels of mrp3 (Fig. SB). Mrp4 seems to be 
expressed at lower relative levels in the small intestine, but is absent from 3T3 
cells. The PCR product from cDNA reverse transcribed from whole tail RNA 
was sequenced, and the results confirmed that the m/p/p/f sequence of the 
mRNA expressed in the tail is the same as that of the m/p4 cDNA cloned from 
day 13.5 placentae. 
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The mouse tail skin and the mouse ear skin express unique keratins that 
are different from those found in normal backskin. Therefore, RNA from the ear 
also was subjected to diagnostic RT-PCR and compared with the results from 
tailskin RNA (Fig. 5B). Although mrp/plfcDNA was not detected in most normal 
backskin samples (Fig. 5A), mrp/plf cDNAs were regularly identified in both the 
ears and tailskin where mrp4 was the only identified mrp/plf {F\g. 5B). Mrp4 also 
was the major mrp/ptf species detected in the remainder of the tail after the skin 
was removed (data not shown). 
Identification of the mrp4 promoter 
To identify the m/p4 promoter, a series of cosmid clones containing mrp/pff 
sequences were screened for the presence of the mrp4 gene by several PCR-
based assays. First, diagnostic PCR was performed between exons 3 and 4 on 
isolated cosmid clones containing m/p/p/f hybridizing genes in order to identify 
specific mrp/plf-conta\ning cosmids. Individual clones were identified that 
produced the predicted restriction digestion pattern for each of the mtp/plfs. 
Clear restriction patterns were obtained for five cosmid clones; two cosmids gave 
patterns specific lor plf1 (cos4 and cos5), two gave m/p3-specific patterns (cos2 
and cos3) and one gave the mrp4 restriction pattern (cos6). Clones that 
produced PCR products with mrp/plf-specific digestion patterns were also 
sequenced across the promoter region after PCR amplification starting with a 
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primer in the common 5'UTR. By this method, the promoter known as plf42 was 
shown to be contiguous with the gene encoding p/fl, the promoter plf149 
corresponded to mrp4 and the mrp3 promoter corresponded to mrp3 cDNA. 
To confirm the promoter cONA contiguities deduced from the cosmid 
clones, RT-PCR was performed using 5* primers that would amplify transcripts 
initiating at upstream promoters located between 140 or 230 basepairs of the 
normal transcriptional start site (data not shown). When performed on RNA from 
the tail (using primers DAP1 and NUE5), the promoter for mrp4 was confirmed to 
be plf149. Similariy for 3T3 cells, which express predominantly plf1, RT-PCR 
using M3V55 and UE5 produced upstream transcripts that corresponded to the 
plf42 promoter. As expected, the placental mrp3 cDNA was found to be linked to 
the mrpS promoter when RT-PCR was performed using DAP1 and NUE5. 
Localization of iMRP4 in the hair follicles of the mouse tail 
To determine the location of the MRP4 protein in the adult tail, 
immunohistochemistry was performed using a rabbit polyclonal anti-MRP/PLF 
serum. Binding of anti-MRP/PLF antibody was detected in the hair follicles of the 
tail skin (Fig. 7). The location of MRP/PLF in the hair follicles appeared to be 
limited to the keratinocytes that make up the outer root sheath. Pre-immune 
sera did not stain these structures. 
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DISCUSSION 
The MRP/PLFs exhibit several very Important biological activities. They 
stimulate proliferation, angiogenesis and inhibit differentiation. However, until 
this report, they have only been demonstrated to be expressed in the placenta. 
There are between four and six mrp/plf genes in the mouse (20) and three of the 
cONAs have been previously identified. Here, we describe the identification and 
cloning of a fourth mrp/plf {mq34j that is transiently expressed during gestation in 
a manner distinct from the other mrp/ptfs and which is uniquely expressed in the 
tail and ear of adult mice. 
MRP4 is more different in sequence from the other three MRP/PLFs than 
are the other three MRP/PLFs from each other. Whereas MRP4 is 91% identical 
with PLF1. the other three MRP/PLFs (PLF1, PLF2 and MRP3) are 99% identical 
with each other. The MRP4 protein also is differently glycosylated because two 
differences in the amino acid sequence result in the loss of two potential N-
glycosylation sites from MRP4 compared with the other MRP/PLFs. This 
difference in glycosylation might alter the stability of the protein, its interaction 
with receptors or its ability to move from one tissue to another. For example, we 
have demonstrated that the 27-kDa form of MRP/PLF in the placenta that we 
identified as MRP4 is not found in the bloodstream or the amniotic fluid of the 
pregnant mouse as are other MRP/PLFs (14). 
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Mrp4 expression peaks on day 12 of gestation. This is at a time during 
which expression of the other two mrp/plfs is decreasing (6,14. 31). 
Interestingly, it is the same time at which proliferin-related protein (PRP) peaks 
(32). PRP is closely related in sequence to the mrp/plfs with 37% identity to 
PLF1 in amino acid sequence and 96% identity to PLF1 in the first 97 
nucleotides (6). PRP opposes the effect of bFGF on angiogenesis, and the 
delayed increase in PRP expression in the placenta is proposed to effect a rapid 
inhibition of the angiogenic effects of the MRP/PLFs (16). Similar to MRP4, PRP 
is not found in the amniotic fluid, but unlike MRP4, PRP is found in matemal 
serum (32). 
Individual members of the m/p/p/f family are differentially regulated in vivo 
in both tissue-specific and temporal patterns. As well as being expressed in the 
placenta, the mrp/plfs are expressed in the small intestine, tail, and ear and 
sometimes were observed in the stomach. Although not detected in most 
samples of backskin, occasionally samples showed low levels of mrp/plf 
expression. This expression is mainly of mrp3 (Fassett and Nilsen-Hamilton, 
manuscript in preparation). The mrp/plfs were not detected in the liver, lungs, 
ribs, and large intestines. Different mrp/plf genes are expressed in different 
tissues. Plf1 is the major form of mrp/plf mRNA expressed in the stomach, small 
intestine and 3T3 cells, while mrp3 is the major form expressed by the 
midgestational placenta. Mrp4 is the only form of mrp/plf expressed in the ear 
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and tail skin. As we have shown a broader tissue expression pattern of the 
mrp/plfs beyond the placenta which is their site of highest expression, so are 
other genes of the prolactin/growth hormone family found to be expressed in 
high levels in one primary tissue and secondarily in other tissues. Beyond its 
primary site of expression in the pituitary, prolactin, the evolutionary precursor to 
the rodent utero/placental gene family, also is expressed in other tissues, 
including the dermis (33). The placental lactogens I and II are expressed in the 
testes in addition to their high levels of expression in the placenta (34). 
By immunohistochemistry, the MRP4 protein is localized in the 
keratinocytes of the outer root sheath of the hair follicle in the tail. These cells 
may not be the site of the protein's initial synthesis, but they are apparently the 
site of highest accumulation of MRP4. Thus, it is likely that the keratinocytes are 
either the source of MRP4 or the site of its action or perhaps both. 
The observation that the mrp/plfs are expressed in a tissue-specific manner 
suggests that these genes are regulated by distinct factors. As well, the site of 
expression of MRP4 is specific to the location in the body, e.g., tail vs. back. 
This observation parallels those of the keratin gene family where the keratin pair 
of 48 kDa and 65 kOa is expressed specifically in suprabasal cells of the tail 
epidermis, in the filiform papillae of the tongue, and at low levels in suprabulbar 
cells of newborn hair follicles (35). In mice, a 70-kDa keratin {mk2e) is 
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expressed specifically in the ear, tail and footsole epidermis (36). The ear and 
tail are also the specific sites of mrp4 gene expression. 
Here we have shown that the promoter for mrp4 is the previously cloned 
plf149 promoter and the plf42 promoter as being the sequence upstream of the 
plf1 coding sequence (37). Although 98% homologous to the promoter for plf1 
(plf42), the mrp4 (plf149) promoter is not stimulated by the addition of serum (37) 
or bFGF (38). Interestingly, there are a number of differences t>etween the 
plf149 and mq33 and plf42 promoters that affect recognizable regulatory 
elements. One of these changes affects the FGF response element (FRE) 
present in which is disrupted in the other two promoters (38). This and 
other alterations in regulatory sequences are likely to be responsible for the 
differential expression of the mrp/plfs in mouse tissues. 
In summary, we have identified a fourth mrp/plf qeiye with a distinct tissue 
expression pattern from the other genes. Despite the high identity in 
nucleotide sequence, it is striking that a large number of the differences in 
nucleotide sequence of the first 550 bp of these promoters result in alterations of 
recognizable regulatory element sequences. These observations suggest that 
the /71/p/p/f family may have evolved to take advantage of specific combinations 
of transcriptional regulatory elements for the regulation of m/p/p/f gene 
expression in particular cell types or under special physiological conditions. The 
resulting MRP/PLF proteins, which are also 91% to 98% identical in amino acid 
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sequence, may not differ in their function. However, there may be other 
differences. For example, the difference in giycosylation of MRP4 compared 
with MRP3 and PLF1 could result in altered stability or tissue access for MRP4, 
or MRP4 may interact with a different set of receptors. Thus we suggest that 
MRP4 may function as a growth factor and/or angiogenesis factor in the vicinity 
of the hair follicle in the tail and ear as MRP3 and PLF1 are proposed to do in 
the placenta. 
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FIGURES 
Figure Diagnostic RT-PCR of mrp/plfcDNAB. Top panel. Diagram to show 
how digestion with the restriction enzymes BsoFI and BstXI results in different 
sized restriction fragments for each mrp/plf. Resolution of these fragment by 
agarose or acrylamide gel electrophoresis followed by their quantitation provides 
estimates of the relative amounts of each mrp/plf mRNA in individual samples. 
Bottom panel. The mrp/pHs are distinguishable by their digestion pattem. Plf1, 
plf2, and mrp3 cDNAs and placental cDNA from various gestational days were 
amplified and digested with BsofI and Bstxl as described in panel A. The 
resulting fragments were run on an 8% polyacrylamide gel. The top arrow 
indicates the 564-bp fragment that does not digest at either internal restriction 
site. 
Figure 2. Sequence comparisons of MRP4 with other MRP/PLFs. The 
nucleotide sequence of plf1 is compared with that of mrp4. The complete protein 
sequence of MRP4 is shown and sequences of the other three proteins are 
shown only where they differ from MRP4. The signal sequence is underiined. 
The amino acids that are changed in the N-glycosylation sites are italicized.The 
three putative glycosylation sites are identified by the boxes. The numbers to the 
left of the protein sequences show the position of the first amino acid in each row 
In the PLF1 protein sequence. Note that after position 166, the MRP4 sequence 
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is two amino acids short of the other three sequences due to the deletion of 
amino acids 167 and 168 from the MRP4 sequence. 
Figures. Placental expression of the m/p/pASs. A, upper panel: 
Quantitation by diagnostic RT-PCR of the proportional expression of pifl, mrp3. 
and mrp4 by the placenta through gestation. These data were also used, along 
with the total amount of RNA determined by Northem blot analysis, to determine 
the relative amounts of each of the genes in gestation (13). The results 
shown are the average of four separate experiments in which different placental 
samples were analyzed. The results were averaged to obtain the results shown. 
As a result of different combinations of samples in each experiment, the values 
are the average of two (days 8,10,12,13) or three (days 9,11,15) separate 
values. Shown are the sample standard deviations. A, lower panel: The 
expression of mrp4 was analyzed during gestation using the restriction 
endonuclease Ndel, which digests mrp4, but not the other identified mrp/ptfs. 
Shown are averages of two experiments. B. Digestion pattem of the mrp/plf 
amplicons with Ndel. 
Figure 4. Western blot of MRP/PLFs produced by transiently transfected 
COS cells compared with the MRP/PLF proteins present in the placenta. 
COS cells were transiently transfected with mammalian expression plasmids for 
MRP4 (4) and PLF1 (1) as described in Materials and Methods. Some cells (IT, 
4T) were treated with 5 ^g/ml tunicamycin for the last 24 h of incubation. 
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Medium from the transfected cells and cell lysates were resolved by SDS-PAGE. 
1, COS cells transfected with pcONA3-PLF1; 4. COS cells transfected with 
pcDNA3-MRP4; IT, 4T, tunicamycin treated cell cultures transfected with 
pcDNA3-PLF1 or pcDNA3-MRP4 respectively; ell and e14. homogenates of 
day 11 and 14 placentae respectively. The positions of three molecular weight 
markers, ovalbumin (45 kDa), carbonic anhydrase (30 kOa) and myoglobin (18 
kDa) are shown. The positions of PLF1 and MRP4 in cells and culture medium 
are marked on the left of the figure and the positions of PLF1 and MRP3, and 
MRP4 in the placental homogenates are noted on the right of the figure. The 
position of the nonglycosylated forms of PLF1 and MRP4 is also shown (NG). 
Figure 5. Diagnostic RT-PGR demonstrates m/p/pif expression in several 
murine adult tissues. A. (top three panels) sequences in RNA isolated 
from 2-month old CF-1 mouse liver, lungs, skin, tail, ribs, small intestine, large 
intestine, and 3T3 cells were amplified by RT-PCR as described in Material and 
Methods. A control of water alone was also included. The initial reaction to 
create mrp/plf cDNA was done in the presence (+RT) or absence (-RT) of 
reverse transcriptase. The third panel down shows the result of amplifying with 
primers for G3PDH. B. (bottom panel) Mrp/plfcDNAs from ell placenta, adult 
tail, ear, adult small intestine, and 3T3 cells were digested with BsoFI and BstXI. 
Shown are the results from two experiments with the two lanes on the right from 
the second experiment. The tail samples in the two experiments were from 
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different animals. The results from digestions of the fragments isolated from 
plf1, plf2, mrp3 and mrp4 standard samples are also shown. 
Figure 6. Immunodetection of MRP in the tail of the adult mouse. Sections of tail 
from a non-pregnant female FVB mouse were stained with anti-MRP/PLF antibody 
(A, top panel) or pre-immune sera (B, bottom panel). Antibody stains the outer root 
sheath of the hair follicles (brown color, top panel). Similar results were obtained for 
male and female, CF-1 and FVB mice. 
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CHAPTER 4: MRP3, A MITOGEN-REGULATED PROTEIN/PROLIFERIN 
GENE EXPRESSED IN WOUND HEALING AND HAIR FOLLICLES 
A paper to be submitted to the journal Endocrinology 
John T. Fassett^ '^  and Marit Nilsen-Hamilton '^^ '^  
ABSTRACT 
During cutaneous wound healing, a marked increase in the local expression 
of growth factors results in increased migration and proliferation of the cells 
responsible for tissue repair. The MRP/PLF Mitogen regulated protein/proliferin; 
proteins are growth factors and angiogenesis factors. Here it is demonstrated 
that mrp3 is induced in wound edge keratinocytes during cutaneous wound 
healing and also temporally appears in the outer root sheath of the hair follicle 
during the late anagen phase of the hair cycle. In cultured keratinocytes, mrp3 is 
induced by keratinocyte growth factor but not by epidermal growth factor or 
transforming growth factor type a. Transgenic mice, expressing lacZ under the 
combined control of the cytomegalovirus immediate eariy (CMV-IE) enhancer 
^Molecular, Cellular and Devetopmental Biology Program and the Departments 
of ^Zoology and Genetics and ^Biochemistry, Biophysics and Molecular Biology, 
Iowa State University, Ames, lA 50011, USA 
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and the mq33 flanking sequences, demonstrate wound and hair cycle-induced 
transgene expression, showing that elements within the flanking regulatory 
sequences of the mrp3 gene are involved in the activation of mrp3 in response to 
these events. The results reported here suggest that mqo3 may participate in 
wound healing and in the hair follicJe cycl as a growth factor and/or angiogenesis 
factor. 
INTRODUCTION 
A hallmark of wound healing is the release of growth factors at levels much 
higher than are typically found in nonwounded skin (Wemer et a!., 1992). 
Fibroblast growth factor (FGF) family members stimulate angiogenesis (Clark, 
1996), as well as migration and proliferation of fibroblasts and keratinocytes 
(Tsuboi et a/., 1992; Wemer, 1998). Expression of a dominant negative FGF7 
receptor in the skin of mice delays wound healing (Wemer et a!., 1993). The 
application of bFGF enhances wound healing in healing-impaired db/db mice 
(Tsuboi and Rifkin, 1990). Thus, re-epithelialization and tissue repair are likely to 
be mediated in part by the ability of skin cells to appropriately respond to FGFs 
and other growth factor signals. 
Growth factors, including FGFS, FGF7, EGF, and TGFa are also involved in 
hair follicle morphogenesis, as evidenced by the hair-associated abnormalities 
Keywords: mrp/plfl wound / hair follicle / keratinocyte / KGF 
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linked to mutations or introduced knockouts of these genes or their receptors 
(Guo et ai, 1996; Hebert et al., 1994). The hair follicle contains stem cells that 
are likely to contribute to cutaneous wound healing by providing a source of the 
keratinocytes that migrate and proliferate to repair the wound (Cotsarelis et al., 
1990). 
The mitogen regulated protein/proliferins (mrp/plfs) are a group of highly 
homologous, well characterized growth factor-inducible secondary response 
genes and memt)ers of the prolactin/ growth hormone ^ mily (PRL/GH). In 
immortalized mesenchymal ceils derived from mouse embryos (3T3 cells), 
m/p/p/f expression is increased in response to bFGF and other growth factors 
(Niisen-Hamilton etal., 1980). Expression of mrp/plf is greater in growing than in 
quiescent cells (Linzer and Wilder, 1987). This may be in part explained by the 
fact that transforming growth factor type p (TGPP) inhibits m/p/p  ^expression in 
quiescent but not in growing cells (Chiang and Niisen-Hamilton, 1986). 
There are between 4 and 6 mrp/p/f genes (Jackson-Grusby et al., 1988), 
and the four cloned cDNAs (pifl, plf2, mrp3, and mrp4) are highly identical to 
one another (Connor et al., 1989; Fassett etal., 2000). Although some 
non-placental cell lines express mrp/ptfs in vitro, the only tissue identified in the 
mouse in which expression was identified until recently is the placenta 
(Linzer et al., 1985). M/p/jo/f expression is localized to the trophoblastic giant 
cells, which secrete high levels of m/p/^ /f during mid-gestation (Lee et al., 1988; 
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Nilsen-Hamilton etal., 1988). Placental mqj/plf is believed to be an angiogenesis 
factor in the fetal placenta and activates the mannose 6-phosphate receptor 
(Jackson et al., 1994). It is also a growth factor for the uterus that acts through a 
separate receptor in the uterus that does not recognize mannose 6-phosphate 
(Fang et al., 1999; Nelson et al., 1995). Thus, the MRP/PLFs are t)elieved to 
coordinate aspects of fetal and maternal development during pregnancy through 
their ability to regulate cell proliferation and angiogenesis. 
Because growth factors are expressed at high levels during wound healing, 
and the mrp/ptfs are highly upregulated by growth factors in 3T3 cells, we 
investigated the possibility that expression might also be increased during 
wound repair. Here we demonstrate that mrp3 is expressed specifically in 
suprabasal keratinocytes at the wound site, and its expression is regulated 
temporally during cutaneous wound healing. MRP/PLF protein and RNA 
expression are also regulated during the hair follicle cycle, where 
immunohistochemistry reveals the protein predominantly in the outer root sheath. 
The same distribution and regulation of expression was found in transgenic mice 
expressing a lacZ transgene under combined control of the cytomegalovirus 
immediate early (CMV-IE) enhancer and the mrp3 flanking sequences. We also 
show that mrp3 expression is induced by KGF in primary cultures of 
keratinocytes. These data suggest that mrpS plays a role during cutaneous 
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wound repair and in the hair follide cycle. A likely regulator of mrp3 gene 
expression in the skin is KGF. 
RESULTS 
Mrp/plf Genes Are Expressed in Regenerating Epidermis 
To determine if the MRP/PLFs are produced during wound healing, full 
thickness wounds were created on the backs of mice and. at various times after 
wounding, immunohistochemistry was performed on the wounded skin tissue by 
using anti-MRP/PLF. Antibody staining was most evident in the suprabasal 
keratinocytes at the wound edge between days 4 and 5 after wounding (Fig. 1 A). 
Staining was less evident before hyperproliferation of wound edge 
keratinocytes, which occurs on about day 4, and was also less intense as the 
wound became reepithelialized after day 7.5 (data not shown). There was little 
staining in basal keratinocytes. Stain was occasionally found over the outermost 
terminally differentiated keratinocytes. Often, keratinocytes expressing 
MRP/PLFs were located along the hair follicles near the wound. Staining was 
also occasionally detected in the outer root sheath of hair follicles not associated 
with the wound (not shown). There was no stain using pre-immune sera (Fig. 
1B). 
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Mrp3 Is the Major Mrp/plf Gene Expressed During Wound Healing 
To determine whether mrp/p/f genes are expressed in wounded tissue, total 
RNA was extracted from wounds at different times after wound healing and 
subjected to RT-PCR. G3PDH was also amplified from the same cONAs in 
parallel analyses to serve as controls for sample quality. MqVplfmRNA was 
detected in wound tissue after one day of wounding and seemed to be present at 
the highest levels at 2.5 days after wounding (Fig. 2A). 
To determine which mrp/plfs are expressed during wound healing, the four 
known mrp/plf gene products were distinguished by diagnostic RT-PCR as 
described in Materials and Methods. A portion of each sample shown in Fig. 2A 
was amplified for an additional single round in the presence of ^ ^P-dCTP, 
digested with Bsof1 and Bstx1, and separated on a nondenaturing 10% 
polyacryiamide gel. Standards for individual mrp/pff forms were treated similarly 
and used as controls for the expected fragments. As shown in figure 2B for day 
2.5, mrp3 makes up most of the mrp/plf vnRNA found in skin wounds. 
Keratinocyte Regulation of Mrp/p/f Expression in Response to Growth 
Factors. 
To better understand which growth factors may be inducing mrp/plf 
expression at the wound edge, newbom mouse keratinocytes were isolated and 
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treated with KGF (FGF7), EGF, or TGFa. Mrp/plf gene expression, as measured 
by Northern blot analysis, was increased in response to KGF, whereas EGF and 
TGFa had no effect (Fig. 3A, B). As in the wound, mrp3 was the major form of 
mqj/plf expressed by FGF-stimulated mouse keratinocytes although some pifl 
was also expressed (Fig. 3C). By comparison, 3T3 cells expressed mostly pifl. 
Mrp3 Transgene Expression in Response to Wound Healing 
Transgenic mice carrying the CMV/MRP3/lacZ/3U DNA construct were 
examined for P-gaiactosidase expression in response to wound healing. In full 
thickness cutaneous wounds in the back, staining was evident between 1 and 3 
days after injury in one of two independently isolated transgenic lines containing 
the complete CMV/mrp3 construct (Fig. 4A) and in two independent transgenic 
mouse lines containing a CMV/MRP3/lacZ construct that contained about 600 bp 
instead of ~3kb of 3' mrp3 UTR. One of the latter two lines also showed staining 
in the panniculous camosis. Both the location and the time course of transgene 
expression was similar to endogenous mrpS expression 
In all four transgenic lines containing the CMV/MRP3/lacZ construct with 
~600bp or ~3' 3kb of mrp3 sequence, tail injury resulted in expression of lacZ 
specifically in the skin around the edge of the wound (Fig. 4B). No staining was 
observed in tissue fixed immediately after wounding (Fig. 4C). In a control 
transgenic mouse line containing the CMV-IE enhancer but only 49bp of the 
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mrp3 promoter, lacZ was expressed constitutively throughout the skin and in 
most other organs tested as well (not shown). 
Presence of MRP/PLFs in the Hair Follicle 
In the course of these studies it was noticed that some hair follicles also 
stained for MRP/PLF. The protein was detected by immunocytochemistry using 
anti-MRP/PLF but not with preimmune serum (Fig. 5A.B). MRP/PLF staining 
was strongest in the outer root sheath of the hair follicle and absent from the 
bulb. The morphology of the follicles that were stained with anti-MRP/PLF 
indicated they were in the anagen stage of the hair follicle cycle. 
Regulation of Mrp/ptf Genes During Hair Follicle Morphogenesis 
To analyze expression of the mrp/plf genes during the hair follicle cycle, 
black coated C57/BL6 x CF-1 hybrid mice were depilated and skin samples were 
collected at various times aftenA/ards. Staining was evident in some follicles in 
the outer root sheath during mid-anagen (day 8) and was more extensive at late 
anagen (day 17.5) of the hair follicle cycle. No staining was evident when 
preimmune serum was used (Fig 5C-H). Staining was also seen in the 
outermost epidermal layers. 
RNA isolated from other tissue samples in the same experiments were 
analyzed by diagnostic RT-PCR (Fig. 6). The expression of mrp/plfs was highest 
by day 17.5 (Fig. 6A) which corresponds to late anagen (Pena et al., 1999). 
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Mrp3 was the predominantly expressed mrp/p/f during normal hair follicle cycling 
(Fig. 6B). Smaller proportions oi plf1 and mrp4 were also expressed. 
The CMV/MRP3/lacZ/3U transgenic mice showed strong ^ -galactosidase 
staining in the outer root sheath of anagen hair follicles (Fig. 7A). Staining in the 
more external elements of the hair follicles was generally darker and more 
consistent than staining near the bulb region. This could have been due to 
limitations in the penetration of the X-gal through the tissues. Consequently, the 
distribution of P-galactosidase expression was also determined in hair follicles 
that had been plucked from the animal prior to staining (Fig 7B). 
DISCUSSION 
For many years, the only reported in vivo sites of m/p/jD/f expression were 
the trophoblastic giant cells of the placenta (Lee et ai., 1988). Recently we have 
demonstrated the selective expression of one member of the m/7v)9/f family 
known as mrp4 in the hair follicles of the tail (Fassett et ai, 2000). Here we 
show that another member of this family, mrp3 is selectively expressed in 
keratinocytes during wound healing and in the late anagen hair follicle. 
Mrp3 gene expression starts soon after wounding although the MRP3 
protein is not detected by immunohistochemistry until it has accumulated to high 
levels 4-5 days after wounding. The increase in mrp3 gene expression revealed 
by RT-PGR begins early in the inflammatory stage and continues through the 
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granulation stage of wound healing, the latter being the period of keratinocyte 
proliferation and the re-epithelializatlon phase of wound healing (Clark. 1996). 
Keratinoycte growth factor (KGF, also FGF-7), a potent keratinocyte 
mitogen (Werner. 1998) increases ni/p3 expression in keratinocytes in culture. 
In vivo, dominant negative KGF receptors cause severe defects in wound 
healing (Werner eta!., 1994), whereas KGF iigand knockouts show normal 
wound healing but have abnormal coats (Guo et a/., 1996). These results 
suggest that signaling through KGF receptors is crucial for wound healing but the 
KGF Iigand itself is not essential. This result is consistent with the observation 
that several members of the FGF family interact with fgfr2, the KGF receptor. 
Neither EGF norTGFa increased mrp/p/f expression by keratinocytes, even 
though these are mitogens for keratinocytes and stimulate expression in 
3T3 ceils (Nilsen-Hamilton et al., 1980). Here it is relevant that plf1 is the major 
mrp/plf gene expressed in 3T3 cells, and the predominantly expressed gene in 
keratinocytes is mrp3. The mrp3 promoter but not the pifl promoter is stimulated 
by FGF in 3T3 cells (Mohideen et al., 1999). 
MRP3 was not detected in the keratinocytes found at the very surface of 
the wound that are believed to be migrating across the wound. In humans, the 
migrating keratinocytes display the highest level of immunostaining for the 
cleaved and activated form of TGFp (Kane etal., 1991). MRP/PLF expression 
by 3T3 celts is inhibited by TGF3 (Chiang and Nilsen-Hamilton, 1986). Results 
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here showing that 3T3 cells express mostly plf1 suggest that these previous 
studies demonstrated that TGF  ^ inhibits the expression of plf1. However, in 
3T3 cells stably transfected with 2 kb of the mrp3 promoter upstream from a CAT 
reporter gene, TGF0 also inhibited the mrp3 promoter activity (Mohideen and 
Nilsen-Hamilton, unpublished). Thus, mrp3 expression may be suppressed by 
TGFp in migrating keratinocytes. 
Although cultured keratinocytes are not physiologically equivalent to 
wounded skin, the regulation of mrp/plf 'm response to growth factors may be 
similar to that in vivo. KGF is highly expressed by the dermis from 24 h after 
wound healing through at least seven days (Werner et al., 1992). Mrp3 is 
expressed over this same time In the suprabasal keratinocytes at the wound 
margins. During wound healing, proliferation of the underlying basal layer results 
in a greatly thickened layer of suprabasal keratinocytes. Although mitotic figures 
are evident in the suprabasal layer, the majority of cell proliferation in the wound 
is in basal keratinocytes. MRP3 might t)e part of a positive feedback mechanism 
by which the suprabasal cells stimulate further proliferation of the cells in the 
underlying basal layer. This mechanism would parallel that of PLF1, a growth 
factor for primary uterine cells (Nelson et al., 1995). 
The MRP/PLFs signal through two different receptor types: a unique 
MRP/PLF receptor (Nelson etal., 1995) and the IGF-ll/mannose-6-phosphate 
receptor (Rogers etal., 1990; Volpert eta!., 1996). In sheep, IGF-II receptors 
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are expressed in the germinal matrix with peak expression during late 
anagen/eariy catagen and in the dermal papilla with peak expression during 
telogen (Nixon et ai, 1997). If the IGFII receptor is similarly expressed in the 
mouse, then the cells expressing these receptors are possible targets for the 
MRP/PLFs that are expressed in late anagen. 
The FGF family stimulates proliferation and angiogenesis and are involved 
in cutaneous wound healing. Expression of a dominant negative FGF7 receptor 
in the skin of mice delays wound healing (Werner et ai, 1993), and the 
application of bFGF enhances wound healing in healing-impaired db/db mice 
(Tsuboi and Rifkin, 1990). Some FGFs are also produced in hair follicles: Fgf5 
and Fgf7 mRNAs are present in the outer root sheath during anagen IV (Hebert 
et al., 1994; Rosenquist and Martin, 1996). Messenger RNAs encoding several 
FGF receptors are also present in the hair follicle during anagen; Fgfirl mRNA in 
the dermal papilla, Fgfir2 RNA in hair matrix cells near the dermal papilla, Fgfr3 
mRNA in pre-cuticle cells in the periphery of the hair bulb, and Fgfr4 RNA in cells 
in the periphery of the hair bulb and the inner and outer root sheath in the lower 
half of the follicle neck. These FGFs and their receptors are likely to be active 
after the period of follicle growth tiecause proliferative cells are found in the outer 
root sheath during catagen and telogen (Tezuka et ai, 1990). KGF is specific for 
fgfr2 (Miki et ai, 1992) but fgfr4 is expressed by the outer root sheath cells. 
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Thus, it is possible that an FGF other than KGF stimulates expression in 
these cells. 
Expression of mqs/plf 'in the skin was confined to the wound keratinocytes 
and epithelial cells of the outer root sheath cells of the hair follicle. In these cells, 
mrp3 was the major form expressed. Mrp3 expression was also observed in skin 
containing hair follicles in late anagen where pifl and mrp4 were also found in 
smaller relative amounts. The expression of small proportions of plfl and mrp4 in 
hair follicles and not in healing skin could reflect the different mouse strains used 
in the wound healing (FVB) and hair cycle (C57/BL6 x CF-1 crosses) studies. 
However, we did not observe differences in m/p/p/f types expressed in placental 
tissues from CF-1 and Balb/c mice (Fassett et al., 2000). Recently, we have also 
observed expression of predominantly plf1 in stomach epithelia (unpublished) 
and plf1 and mrp3 in the small intestine (Fassett etaL, 2000), whereas mrp4 is 
constitutively expressed in the skin of the adult tail (Fassett et al., 2000). Thus, 
mice seem to have evolved mechanisms to express different mrp/plf forms in 
different epithelial tissues. 
Transgenic mice containing a CMV/MRP3/LacZ transgene expressed 
3-galactosidase in the wound and hair follicles in the same cellular locations and 
with the same time course as seen by RT-PCR for endogenous mRNA 
expression and by immunocytochemistry for MRP/PLF protein localization. In 
these studies, the presence of the CMV-IE enhancer seemed to increase 
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expression from the mrp3 promoter. In other studies, the CMV-IE enhancer did 
not efficiently increase transgene expression in the skin from the CMV promoter 
(Sawicki et al., 1998). However, the CMV-IE enhancer in combination with the 
chicken p-actin promoter drove p-galactosidase transgene expression strongly in 
many locations in the skin with the highest expression observed in the 
sebaceous gland, epidermis, suprabasal and basal cells of the epidermis, and 
the arrector pili muscle. Expression was not high in the outer root sheath. Thus, 
the promoter (CMV or 3-actin) rather than the CMV-IE enhancer determines the 
pattern of expression of the transgene (Sawicki et al., 1998). We show here a 
different expression pattem of the mrp3 promoter in combination with the CMV-
IE enhancer than previously reported for CMV-IE enhancer with the CMV 
promoter or with the P-actin promoter. Although the presence of the CMV-IE 
enhancer increases the level of transgene expression from the mrp3 promoter, 
the information necessary to determine spatial expression of mrp3 in the wound 
and the hair follicle seems to t)e present in the 1,514 bp proximal mrp3 promoter. 
This transgenic construct also expressed specifically in the giant cells of the 
placenta during gestation which is the major site of mrp3 expression during 
development (Fassett and Nilsen-Hamilton, in preparation). 
If the functions of mrp/plfs in the skin are similar to those proposed for 
mrp/plfs during reproduction then MRP3 might promote proliferation by way of 
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the MRP/PLF receptor (Nelson et al., 1995) and angiogenesis through the IGFII 
receptor/mannose-6-phosphate (Jackson ef al., 1994). 
The timing of mrp3 expression during the late anagen stage of the hair 
follicle cycle is not consistent with an immediate effect of this growth factor on 
angiogenesis because the perifollicular capillary bed regresses after anagen 
(Lachgar et al., 1996). However, although most cell division ceases in the hair 
follicle after anagen, there still appears to be proliferation in the outer root sheath 
(ORS) during telogen (Tezuka et al., 1990). Thus, the immediate role of MRP3 
might be to stimulate ORS cell proliferation at a time when most cell proliferation 
in the hair follicle has ceased. However, a highly glycosylated and very stable 
protein such as MRP3, produced and secreted late in the hair follicle cycle, might 
be adsorbed to the proteins in the extracellular matrix and then released at some 
later time, perhaps directly prior to the anagen phase of the subsequent hair 
cycle when it could act as an angiogenic factor as well as a growth factor for the 
newly forming hair follicle. 
In conclusion, we have shown that mrp3 is expressed in keratinocytes 
during wound healing and in the outer root sheath of the late anagen hair follicle. 
Members of the FGF family are the most likely positive regulators of mrp3 gene 
expression in the skin whereas TGFp may be a negative regulator. Studies with 
transgenic mice suggest that the DNA elements necessary to direct mrp3 
expression in the wound and in the hair follicle are present in the DNA 
103 
sequences flanking the mrp3 coding sequence. On the basis of previous 
findings, we suggest that MRP3, previously identified only in the placenta, is a 
growth factor and an angiogenesis factor that may play a role during wound 
healing and the hair follicle cycle. 
MATERIALS AND METHODS 
Animals and materials CF-1 and FVB mice, originally obtained from 
Charles River (Wilmington. MA), were bred and cared for at the Laboratory 
Animal Facility at Iowa State University under a 12-h light/dark cycle. All animals 
were housed and treated according to current National Institutes of Health 
guidelines. Care was provided by an animal caretaker and an attending 
veterinarian. With the exception of the removal of tail segments, animals were 
killed by CO2 asphyxiation t>efore removal of tissues for the described studies. 
This research was conducted in accordance with the standards set forth in the 
NIH guide for the care and use of laboratory animals. Prior approval was 
obtained from the Iowa State University Committee on Animal Care for all 
procedures performed on the animals used in these studies. 
Polyclonal anti-MRP rabbit sera and preimmune sera were prepared as 
described (Nilsen-Hamilton etal., 1987). Plasmid vector pckt17-2, a modified 
pSP73 (Promega, Madison Wl) was a gift from Christopher Tuggle (Iowa State 
University). KGF was purchased from( R&D Systems; Minneapolis, Minn). 
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Wound healing experiments FVB mice (Charles River Wilmington. MA) 
were used for most wound healing experiments except for those performed on 
transgenic animals, which were FVB or FVB/CF- 1 crosses. To produce wounds, 
adult mice were anesthetized by using Avertin as previously described 
(Papaioannou, 1990), and scissors were used to make 0.5 to 1 cm full thickness 
skin wounds laterally along the back. Two equally spaced nylon sutures (5-0 
ethilon; Ethicon; Somerville, New Jersey) were used to close each 1-cm wound 
in the back. In some cases the tip of the tail was cut off to produce a wound and 
for use in identifying transgenic offspring. At various times after wounding, the 
wound tissue was removed and either fixed for immunohistochemistry or frozen 
in liquid nitrogen and stored at -70°C until used for RNA isolation. 
Depilation experiments C57/BL6xCF-1 mice were used for the depilation 
experiments so that the stage of hair follicle growth could be monitored (Paus et 
al., 1990). For depilation experiments, adult mice (6-8 weeks) were anesthetized 
with Avertin and the hair was removed using a mixture of t}ees' wax and rosin 
(ZIP; Lee Pharmaceuticals, South El Monte, CA). On the specified days after 
depilation (day 0), mice were sacrificed and each sample of depilated skin was 
cut in half for analysis by immunohistochemistry and RT-PCR respectively. 
Immunohistochemistry Animals were killed on days 0 through 10 after 
wounding or 2.5 through 17.5 days after depilation. Tissues were immediately 
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fixed in 4% paraformaldehyde In PBS (0.14 M NaCI, 2.7 mM KCI, 4 mM 
Na2HP04, 14.7 mM KH2PO4, pH 7.4) for 1-2 h at 4nC. Samples were then 
rinsed in PBS and stored in 70% ethanol until sectioned. For immunodetection 
of MRP, 6 -pm sections were rehydrated and stained as previously descrit)ed 
(Alien and Nilsen-Hamilton, 1998) by using a polyclonal rabbit antl-MRP/PLF 
serum (89rb13a) or a pre-immune serum from the same animal, each at a 
dilution of 1/500. Primary antibody was detected using biotinyiated goat 
antirabbit and horseradish peroxidase conjugated to avidin and was visualized by 
a peroxidase substrate, diamino benzidine tetrahydrochloride (ABC kit; 
Vectastain; Burlingame, CA). Samples were counter-stained with hematoxylin 
and eosin, dehydrated, and mounted with Permount (Fisher Scientific, Pittsburg 
PA) with a coverslip on top. 
RNA isolaticn, RT-PCR, and Diagnostic RT-PCR Frozen tissue was 
pulverized in liquid nitrogen using a mortar and pestle, and total RNA was 
isolated by using Tri-Reagent (Gibco BRL, Gathersburg, MD) according to the 
manufacturer's instructions. Reverse transcription and RT-PCR were performed 
as previously described (Fang et al., 1999; Fassett et ai, 2000). For PCR of 
mrp/p/f cDNAs, the following primers were used; DEI; 
5'TAAGCCTGGGTAGGACTCTGCA 3' (+42 tO +63), UEV; 
5'CATGATATTTCAGAAGCAGAGCAC3' (+776 to +754). For G3DPH, the primers used 
were 5'TGTGGATGGCCCCTCTGGAAA3' (+601 to +621) for the upstream primer and 
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5'GTTTCTTACTCCTTGGAGGC3' (+1063 to +1034) for the downstream primer. 
The diagnostic RT-PCR assay for the mrp/plfs is based on minor 
differences in the cDNA sequences of these closely related gene products that 
result in the presence or absence of restriction sites within the cDNA (Fang et al., 
1999; Fassett et al.. 2000). Amplified, radiolat>eled fragments were digested with 
1 unit each of BsoFi (New England Blolabs; Beverly, MA) and BstXI (New 
England Biolabs) at 55DC overnight in 50 mM NaCI, 10 mM MgCb, 1 mM DTT, 
100 pg/ml bovine serum albumin, 10 mM TrisDHCI (pH 7.9 at 25DC). The 
radiolabeled and digested products were resolved by electrophoresis through 
10% nondenaturing polyacrylamide gels. The gels were dried and exposed to 
film. Positive controls for identification of specific mrfi/plfs were pff1, plf2, mrp3 
and mrp4 cONAs. 
Keratinocyte isolation and culture Newborn mouse keratinocytes were 
isolated as previously described (Harper et a/., 1988) but with some minor 
modifications. Briefly, newborn (day 3-4) mouse skin was removed and 
incubated overnight in 0.25% trypsin in Hanks balanced salts without Ca  ^or 
Mg"  ^(HBS; Gibco BRL). Epidermis was separated from dermis with tweezers, 
and then the dermis was gently scraped with a razor blade to remove remaining 
keratinocytes which were included v^h the epidermis. Epidermis was finely 
minced in Dulbecco-Vogt's modified Eagles medium with high glucose (Gibco 
BRL) and containing 10% calf serum. Larger pieces were removed with a 
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tweezers. The cells were collected by centrifugation at 500 x g for 10 min, 
washed in HBS, and resuspended In serum-free keratinocyte media (Gibco BRL) 
containing 25 pg/ml bovine pituitary extract (Gibco BRL), 2.5 ng/ml recombinant 
EOF (Gibco BRL), 100 units/ml Penn/strep, and 90 pM CaCl2. After being 
cultured ovemight unattached cells were removed and the medium was replaced 
with fresh medium as t)efore but with 75 pM CaCb. Keratinocytes were cultured 
for up to four days before the medium was changed and then the cells were 
cultured for an additional two days without changing the medium. The medium 
was removed and fresh serum-free medium was added without pituitary extract, 
but with the indicated growth factors. Total RNA was isolated after an additional 
14-17 h of culture. 
Transgenic mice Transgenic mice were produced by microinjection of a 
linearized construct as described by others (Hogan et aL, 1994). The full-length 
construct (CMV/mrp3/sisGal/3U) contains the following elements in order of 5' to 
3': A 307 bp Nrul-Bani fragment containing the CMV immediate early enhancer 
from pcDNA-3 (Invitrogen), a 1514 bp Xbal to Psti fragment of the mrp3 
promoter (-1450 to +64), the adenovirus/IgG hybrid intron (Choi et al., 1991), the 
lacZ gene, a Pvull/EcoRI fragment including part of exon five of the mrp3 gene 
to and the 3' poly A site (170 bp) and about 600bp 3' to the Pvull/EcoRI fragment 
in the mrp3 gene. As well, the full-length construct contained the adjacent 
-3,000 bp EcoRI fragment that is 3' to the Pvull/EcoRI 3' end of the mrp3 gene. 
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Partial constructs were also used to prepare transgenic animals. These partial 
constructs consisted of the same portions of the transgene just described, but 
were lacking either the 3kb EcoRI fragment of the m/p3 gene or the 5' mrp3 
sequence from -42 to -1450 of the mrp3 promoter and have -600 bp instead of 
-Skb of the 3' mrp3 UTR. To prepare the construct for microinjection, the DNA 
was digested by Not I to remove it from the vector (pckt17-2), resolved by 
electrophoresis through a 0.8% agarose gel, and purified with Gene Clean 101 
(Bio 101; La Jolla, CA). The eluted DNA was precipitated with ethanoi, washed 
twice in 70% ethanoi, and resuspended in 150 pM EDTA, 10 mM TrisDHCI, pH 
7.4. 
Transgenic mice were identified by PCR analysis of DNA isolated from tail 
or ear tissue, ^alactosidase activity in wounds or hair follicles was detected as 
follows. Tissues were fixed for 40 min in 4% paraformaldehyde in PBS then 
washed 3 times in PBS containing 0.01% Tween 20 and 0.02% sodium 
deoxycholate. The tissue was then stained overnight at 30DC in 0.01% 
Tween 20, 0.02% sodium deoxycholate, 5 mM potassium fem'cyanide, 5 mM 
potassium ferrocyanide, 2 mM MgC ,^ 1 mg/ml X-gal, and 0.1 M sodium 
phosphate, pH 7.4. 
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FIGURES 
LEGENDS TO FIGURES 
Figure 1. MRP/PLF localization in skin wounds Immunohistochemistry of day 
5 skin wounds by using anti-MRP/PLF antisera(A) or preimmune serum (B) 
demonstrates MRP staining localized to keratinocytes at the edge of the wound. 
A, inset In an expanded view of a section of A, staining is seen to be most 
evident in the suprabasal layer of the epidermis, less evident in the stratum 
granulosum, and not evident in the basal layer. BA basal layer; CR, crust; HF, 
hair follicle; SC, stratum comeum; SG, stratum granulosum. Arrows in panel A 
point to sections stained by the antibody. The long vertical arrow in panel B 
shows the centre of the wound. 
Figure 2. Mrp/pif RHA is expressed during wound healing and the major 
form of m/p/plf expressed during wound healing is nup3 A. RT-PCR 
performed on total RNA demonstrates that m/p/pyf mRNA is expressed between 
days 1 and 6 after wounding (top panel). Amplification of GD3PH was similar in 
all samples (middle panel), while no signal was detected in the absence of 
reverse transcriptase (bottom panel). 8. To determine which mrp/plfs are 
expressed during wound healing, portions of the amplified mrp/plf cDt^ As were 
amplified for one additional round in the presence of ^ P-dCTP, digested with 
Bsof1 and Bstx1, and separated on a nondenaturing 10% polyacrylamide gel. 
Samples of the four cloned mrp/plfs (1 through 4) were similarly treated and 
serve as controls to identify the expected fragments. Different fragments result 
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from the digestion of plf1 (318, 246, and 110 bp), ptf2 (289, 275, and 110 bp), 
mrp3 (289, 246, and 110 bp), and mrp4 (564 and 110 bp). Shown are samples 
from two samples of day 2.5 wounds, each removed from a different mouse. 
Figure 3. Mrp/plf3 expression is induced by KGF Newt)om mouse 
keratinocytes were cultured and treated with growth factors as described in 
Materials and Methods. Concentrations of individual growth factors were each 
10 ng/ml. Mrp/plf mRNAs were detected by Northern blot analysis. EGF and 
TGFa did not induce expression of mrp/plfs, and KGF caused a 6-fold induction 
relative to untreated keratinocytes. A. Quantitative results from Northern blot in 
which the value for mrp/plf mRNA level was normalized to the level of G3PDH 
mRNA in each lane. Samples were in duplicate. B. Northern blots comparing 
the effects of EGF and KGF on keratinocyte mRNA levels. C. Diagnostic RT-
PCR shows that cultured keratinocytes express mostly m/p3 compared with 3T3 
cells, which produce mostly pifl. 
Figure 4. The IMRPS promoter directs appropriate expression of iacZ in 
healing wounds Three to four days after wounding, expression of the 
CMV/mrp3/lacZ/3u transgene is detected in cutaneous wounds in the back (A) or 
in tail wounds (B) and (C). Shown is a 4-day old back wound of about 1 cm in 
length (A), 3-day-old tail wound (B) and a second more proximal cut in the same 
tail as in panel B, but which was fixed immediately after wounding (C). Arrows 
point to locations of blue stain. 
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Figure 5. Expression of MRP/PLF in the Hair Follicle The outer root sheath of 
anagen-stage hair follicles were immunostained for MRP/PLF. The section 
shown is a region of skin in an FVB female mouse in which many hair follicles 
were stained. Serial sections were stained with anti-MRP/PLF (A), or pre-
immune serum (B). C57/BL6xCF-1 mice were depilated and sacrificed 2.5 
(C,D), 8 (E.F), and 17.5 (G.H) days later. Skin samples were removed, fixed 
and immunostained with anti-MRP/PLF (D,F,H), or pre-immune serum (C,E,G). 
Arrows point to locations of red-brown stain. The center of the hair-shafts in the 
C57/BL6xCF-1 mice also show as dark because of the high concentration of 
melanin pigment in these hair shafts. 
Figure 6. Mrp/plf mRHA Levels Vary During the Depilatlon-lnduced Hair 
Cycle Total RNA was isolated from depilated skin 0, 2.5, 8, or 17.5 days after 
depilation. Duplicate samples are shown, each from a different animal. A. RT-
PCR was performed as described in Materials and Methods, using primers for 
mrp/plf or g3pdh. B. Portions of the day 17.5 samples shown in panel A were 
analyzed by diagnostic RT-PCR as described in Materials and Methods. The 
duplicate samples are each from a different animal. Mrpd is the major mrp/plf 
expressed during the hair follicle cycle although pifl was also detected. 
Figure 7. The mrp3 Promoter Directs Expression of Lacz to the Outer Root 
Sheath During the Hair Cycle CMV/MRP3/lacZ/3U transgenic mice were 
shaved then depilated. The tissue was fixed, sectioned and stained for p-
galactosidase activity (A). Hair follicles were also plucked, fixed and stained for 
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P-galactosidase activity (B). Transgene expression appears in the same location 
as the immunostain of endogenous MRP/PLF was found in other tissues slices 
(A) and can be seen in similar locations in the plucked hair follicles (B). 
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CHAPTER 5: TISSUE SPECIFIC SPLICING AND EXPRESSION OF AN 
MRP/PLF3 TRANSGENE IN THE PRESENCE OF A UBIQUITOUS ENHANCER 
IS MEDIATED BY FUNCTIONAL VERSUS DECOY PROMOTER SELECTION 
A paper to be submitted to Molecular and Cellular Biology 
J. T. Fassett\ R. T. Hamilton\ and M. Nilsen-Hamilton '^^  
Abstract 
The m/p/p/f genes are expressed specifically in the trophoblastic giant cells at 
high levels during nnidgestation, and are also expressed in some immortalized 
cell lines in response to growth factors. In cell lines, induction is reported 
to occur through transcriptional and post-transcriptional mechanisms. To 
investigate the mechanism by which mrp/plf genes are expressed in a tissue 
specific fashion in vivo, the lacZ gene and an adenovirus/IgG hybrid intron were 
inserted between 1.5 kb of mrp3 promoter and 3kb of 3' sequence. This 
construct was unable to drive detectable P-galactosidase activity in transgenic 
placentae, but was active in transient transfections. If the hCMV enhancer was 
Departments of ^Zoology and Genetics and ^Biochemistry, Biophysics and 
Molecular Biology, Iowa State University, Ames, Iowa 
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added to the 5' end of the transgene, giant cell specific transgene expression 
was observed, suggesting that the m/p3 sequences in the construct can direct 
tissue specific expression in the presence of a ubiquitous enhancer. Removal of 
the 3' 3kb region increased non-specific expression in transgenic embryos, and 
removal of 5' mrp3 sequences resulted in more aberrant expression. It is further 
demonstrated that the mrp3 transgene contains altemate upstream promoters 
that drive transcription of nonsense containing transcripts that may either be 
degraded after splicing or not efficiently spliced. Endogenous m/p/jo/f transcripts 
from these upstream promoters are also produced in vivo. When upstream 
promoters of the mrp3 gene are removed, expression of a reporter gene 
increases in transient transfection, as does the level of spliced transcripts. The 
ratios of spliced to unspliced transcripts also increases in transgenic mouse 
tissues or cells in conditions that promote mrpS expression. This suggests a 
model by which tissue specific expression of the mrp3 gene may be obtained in 
the presence of a strong ubiquitous enhancer. That is, giant cell specific factors 
bound to mrp3 cis acting elements influence selection of the correct promoter for 
activation by the CMV enhancer, while non-specific expression is repressed in 
absence of these factors by selection of decoy promoters that do not result in 
functional transcripts. This model of gene regulation could serve as a fine tuning 
mechanism for tissue specific or growth factor inducible expression in the 
presence of ubiquitous activators of transcription, and could account for what 
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appears to be post-transcriptional regulation of endogenous mrp/plf genes or 
other genes which demonstrate nuclear post-transcriptional regulation. 
Introduction 
Recently, it has k)ecome evident that events associated with transcriptional 
regulation of gene expression may also effect post-transcriptional processing of 
RNA. For instance, the use of different promoters can effect the processing of 
the same downstream transcript and phosphorylation of the carboxy terminus 
domain (CTD) of RNA polymerase II is required for efficient splicing (Misteli and 
Spector, 1999; Steinmetz, 1997). Phosphorylation of the CTD is also necessary 
for recruitment of the protein complex required for addition of the 5' cap of newly 
transcribed RNA (Cho at a!., 1997; McCracken at a/., 1997). It is thus possible 
that differences observed in post-transcriptional regulation of a gene may be 
related to interactions of RNA polymerase with transcription factors that could 
even occur prior to initiation of transcription. Because as much as 1/3 of all 
exon-containing RNA is retained and degraded in the nucleus (Jackson etaL, 
2000), understanding how transcription and nuclear processing may be 
connected is critical for truly understanding mechanisms of tissue specific gene 
regulation. One of many genes that demonstrates highly tissue specific 
expression in the mouse, and also demonstrates transcriptional and nuclear 
post-transcriptional regulation in cultured cells, is the mitogen regulated protein 
gene (proliferin; mrp/plf). 
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Mitogen Regulated Protein (prollferin; mrp/plf) was originally identified as 
a secondary response gene that is up-regulated in 3T3 cells by serum or growth 
factors (Nilsen-Hamilton et al., 1980; Linzerand Nathans, 1984; Nilsen-Hamilton 
et al., 1987). There are between four and six mrp/plf genes in mice (Jackson-
Grusby et al., 1988; Wilder and Linzer, 1986) and promoters have been isolated 
from three of them (Connor et al., 1989; Linzer and Mordacq, 1987). In 
transfected 3T3 cells, mrp3 promoter/reporter constructs are activated by basic 
fibroblast growth factor (bFGF; Mohideen et al., 1999), and in L-cells, plf1 
promoter/reporter constructs respond to TPA or serum stimulation (Linzer and 
Mordacq, 1987; Mordacq and Linzer, 1989). However, endogenous 3T3p/ff 
message increases in response to bFGF or serum without apparent differences 
In transcription as measured by the nuclear run-off assay (Mohideen; thesis, 
Iowa state university; Linzer and Wilder, 1987). Similarity, there is no difference 
in transcription levels between 3T3 cells, that express high levels of mrp/plfs and 
primary mouse embryo fibroblasts, that don't express mrp/plf and from which 
3T3 cells are derived (Edwards et al.. 1987; Malyankar et al., 1994). In both 
cases, higher expression levels appear to be related to post-transcriptional 
processing and increased stability of transcripts in the nucleus (Mohideen thesis; 
Edwards et al., 1987; Malyankar et al., 1994). 
During development, at least three mrp/plf genes (pifl, mrp3, and mrp4) 
(Wilder and Linzer, 1986; Fang et al., 1999; Fassett et al., 2000) are expressed 
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at high levels in the trophoblastic giant cells of the placenta (Lee et al., 1988; 
Nilsen-Hamilton et al., 1988), where they are believed to act as angiogenesis 
factors and uterine growth factors (Jackson et al., 1994; Nelson et al., 1995). Of 
these genes, mrp3 is the most highly expressed, with peak levels occum'ng 
between days 9 and 11 (Fang et al., 1999; Fassett et al., 2000). We have 
recently determined that expression is also detectable in some adult 
mouse tissues under certain conditions (Fassett et al., 2000). Mrp3 expression 
is induced in keratinocytes of the adult mouse during wound healing and the hair 
follicle cycle (Fassett and Nilsen-Hamilton; submitted), plf1 is expressed in the 
epithelia of the stomach (Fassett, unpublished) and small intestine (Fassett et 
al., 2000), and mrp4 is expressed in the mouse ear and tail (Fassett et al., 2000). 
While a number of reports have identified serum or growth factor-responsive 
elements in the /n/p/jD/f promoters, there have been no reports demonstrating 
how mrp/plf gene expression is directed specifically to the placenta or other 
tissues. Based upon studies in cultured cells, it is likely that mrp/plf genes are 
regulated by both transcriptional and post-transcriptional processing 
mechanisms in vivo. 
To better understand how tissue specific expression of the mrp/plf genes 
is regulated in vivo, 1514 b.p. of 5' sequences and 3600 b.p. of 3' flanking 
sequences of the mrp3 gene were analyzed in transgenic embryos for the ability 
to direct expression of a hybrid intron/ lacZ reporter gene. Our results 
132 
demonstrate that the sequences included in the mrp3 transgene alone lack the 
elements necessary to direct detectable expression in transgenic embryos, 
however, giant cell and also wound and hair follicle specific transgene 
expression is demonstrated if a strong heterologous enhancer (hCMV IE) is 
included at the 5' end of the gene. These observations suggest that the 5' and 3' 
flanking regions of the mrp3 gene are able to mediate tissue specificity under the 
influence of a fairly ubiquitous and constitutive enhancer. Importantly, it is also 
demonstrated here that the 5' flanking sequences of the mrp3 gene affect 
splicing of the hybrid intron present in the transgene in a tissue specific fashion. 
Further characterization of this effect suggests that unspliced transcripts are 
derived from transcriptional start sites upstream of the commonly defined 
promoter and they contain translational start codons followed by nonsense 
codons. Transcripts beginning upstream of the normal start site are also 
produced by the endogenous mrp/plf genes in mice and in 3T3 cells and are 
differently processed. These results couple selection of the correct transcript 
initiation site to efficient post-transcriptional processing, and suggest a cryptic 
fine tuning mechanism by which proximal flanking sequences may control gene 
expression even in the presence of a strong constitutive enhancer. 
Materials and Methods 
Plasmids The construct (CMV/1514mrp3/sisGal/3U) contains the following 
elements in order of 5' to 3'; A 507 bp Nrul-BanI fragment containing the CMV 
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immediate early enhancer from pcDNA-3 (lnvjtrogen;Carlsbad, CA), a 1614 bp 
Xba1 to Psti fragment of the mrp3 promoter (-1450 to +64), the adenovirus/IgG 
hybrid intron (Huang and Gorman, 1990), the lacZgene, 170 bp of exon five of 
the mrp3 gene to and including the poly A site, and the adjacent 3600 basepairs 
of the mrp3 gene. Construction of the CMV/1514mrp3/sisGai/3U plasmid 
containing the full-length mrp3 gene was previously described (Fang et a/., 
1999). The construct 1514mrp3/sisGal/3U is the same as above, but missing 
the CMV enhancer. CMV/1514mrp3/sisGal/0.6U is the same as 
CMV/1514mrp3/sisGal/3U, but is missing a 3000 basepair EcoRI fragment of 
mrpS 3' untranslated region. Partial constructs also used for making transgenic 
animals or in cell culture include the CMV(-49)mrp3/sisgal/0.6U construct, 
produced by digesting with Bsu36l and Xbal to remove the mrp3 promoter 
sequences upstream of-48 from CMV/1514mrp3/sisgal/0.6U. The CMV(-
230)mrp3/sisgal/0.6U and CMV(-130)mrp3/sisgal/0.6U constructs were produced 
using PGR to amplify fragments between -230 or B130, and the hybrid intron, 
which were then digested with sac II and spe I (a spe I site was inserted into 5' 
end of fragment as part of the primer) and cloned in place of the 1514 basepair 
mrp3 flanking sequence at the sacll and xba I sites from which the 1514 
basepair sequence was released. The plasmid SVsiscat, which expresses the 
hybrid intron/Choramphenicol transferase gene under control of the SV40 
promoter was kindly provided by Comelia Gorman. 
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Transgenic Mice Transgenic mice were produced by pronuclear microinjection 
as previously described (Hogan). To prepare the construct for microinjection, the 
DNA was digested by Not I to remove it from the vector (pckt17-2), resolved by 
electrophoresis through a 0.8% agarose gel, and purified with Gene Clean 101 
(Bio 101; La Jolla, CA). Eluted DNA was precipitated with 0.3M Na Acetate pH 7 
and two volumes 100% ethanol, washed twice in 70% ethanol, and resuspended 
in 150 JJM EDTA, 10 mM Tris, pH 7.4. FO embryos were dissected from the 
uterus and part of the yolk sac or 1/2 the placenta was removed for analysis of 
DNA or RNA respectively. Transgenic embryos were identified by PGR on the 
yolk sacs as previously descrit>ed (Biotechniques ref*). Embryos identified as 
positive by PGR but which did not produce visible p-galactosidase activity were 
further analyzed by junctional PGR across transgene ends to exclude the 
possibility of contamination by plasmid DNA. To visualize in situ 0-galactosidase 
activity, embryos or adult tissues were fixed by rocking in 4% paraformaldehyde 
in PBS pH7.4 for 40 minutes at 4°C, washed three times in PBS pH 7.4 
containing 0.1% NP40 and 0.2% deoxycholate for 30 minutes each at 23''C, and 
then stained in 5mM potassium fem'cyanide, 5mM potassium ferrocyanide, 2mM 
MgGb, 0.1%NP40, 0.2% deoxycholate, and Img/ml X-gal in 0.1 M sodium 
phosphate, pH 7.4 at 32°G. 
Transfection and cell culture G0S1 cells were grown in DME with high 
glucose (DMEG) with 10 % calf serum and transfected using the OEAE 
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dextran/chloroquine method as previously descrit)ed (Kingston, 1987). Total 
RNA was isolated using Trizol reagent as described by the manufacturer (Gibco 
BRL;Gathersburg, MD). 3T3 cells were cultured in DME with pyruvate (OMEP) 
and 10% calf serum. To stimulate cells with bFGF, cells were plated out at 50% 
confiuency, incubated for 48 h at 370C with 10% CO2, then bFGF was added at 
10ng/ml for an additional 14 to 17 h. 
RT-PCR For RT-PCR, DNA was first removed from 5pg RNA using 100 units 
RNase free DNAse (Gibco BRL) in a 50 pi sample containing lOpg glycogen, 40 
units RNasin, 5mM MnCl2, lOmM Tris-HCI, pH 8.0, for 40 minutes at 37''C. 
Samples were extracted twice with phenol chloroform (25:24:1), pH 8.0, 
precipitated with 0.3M sodium acetate, and two volumes 100% ethanol, and 
washed once in 70% ethanol. The samples were allowed to dry and then 
resuspended in 20 pi of superscript reverse transcriptase buffer containing 0.5 
mM dNTPs and 250 ng of random primers. 3 mM MgCI, 10 mM DTT, 75 mM 
KCI, in 50 mM Tris-HCI (pH 8.3 at 23®C). Each sample was then divided into two 
10 pi portions and heated to 55°C for 5 min. One multiple of each sample 
received 0.5 pi (20 units) superscript reverse transcriptase (Gibco BRL). 
Samples were reverse transcribed for 10 min at room temperature, 1 h at 37°C, 
1 h at 42°C, 10 min at 50°C, and then 15 min at 75°C. 
For amplification of transfected or transgenic cDNAs, the following primers 
were used: 1) for lacZ, ULAC; 5' aactgttgggaagggcgatcg3' (->-129 to -1-108 from 
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lac Z start codon) For mrp/plfs] NUE5 5'catgatatttcagaagcagagcac3'( ->-776 to 
+754), UE3 5' agaagtattgcatctcatgggg 3'(+336 to +315), DAP1; 
5* ccactagtcagagcatgaacat 3' (-229 to -213), M3V55; 
5' ccactagtcatggtatctaggctactt 3' (-129 to -110), D180; 5' taacacgtccttttcttcctg 3' 
(-83 to -63), and D4263; 5' gctaagcctgggtaggactct 3' (+42 to +63). Primers used 
for the hybrid intron and the CAT gene were dsis 5' ccccttctagaattcgctgtctgc 3', 
and UGAT 5' cagcaccttgtcgccttgc 3' respectively. PCR was performed in 25 pi 
reactions containing 0.2 mM dNTPs, 1.5 mM MgCb, 10 pmoles of each primer in 
50mM KCI, 10 mM Tris-HCI, pH 8.3. The PCR cycles were: one cycle at SS'C 
for 30 sec, one cycle at 72''C for 2 min during which time Taq polymerase was 
added. The DNA was then amplified with 32-40 cycles at 95°C for 30sec, 60°C 
for 1 min, and 72°C for 2 min, with one final extension at 72''C for 5 min. 
Samples were separated on 1.5 % agarose gels. RACE; Primers used for RACE 
are UE3;5' agaagtattgcatctcatgggg 3'(+336 to +315). Uil; 5* 
agacactgctgcatgactctagg3'(+ 260 to +238 of intron 1), danch 
5'ggGcacgcgtcgactagtac3', and Anchor primer; 
5'ggccacgcgtcgactagtacgggiigggiigggiig3' (Gibco BRL). 0.2ug RNA was reverse 
transcribed in 50mM Tris-CI (pH 8.3), 50mM KCI, lOmM MgCI, 0.5mM 
spermidine, lOmM DTT with 0.20 mM dNTPs, and 5 pmoles primer ue3 or uil 
and 4 units Rnasin + or - 2.5 units reverse transcriptase. Samples heated for 3 
min at 55°C then put on ice and 0.5 ul AMV RT was added (2.5 units) while the 
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random primed samples stayed at STX. cONA samples were treated with Ipi 
RNAse H for 10 minutes at 37C, then DNA was purified using gene clean (Bio 
101) and 5 pi glassmilk. Samples were resuspended in 10 pi water and 7 pi was 
used for c-tailing in a 10 pi reaction containing lOOmM cacodylate buffer (pH 
6.8), ImM C0CI2, O.ImM DTT, four units terminal deoxynucleotide transferase 
(tdt) and incubated at 37''C for 5 min. and 65^*0 for 5 min. Samples were then 
diluted with 100 pi TE pH 8.0. For PGR, 0.5 pi of c-tailed cDNA were used in a 
12.5 pi reaction containing 10 mM Tris-HGI(pH 9 at 25C®), 50mM KGI, 0.1% 
Triton x-100, 0.2mM dNTPs, using 10 pmoles anchor primer(gibco BRL), and 10 
pmoles uel with the following cycles. 1 cycle of 95°G for 30s, 52°G for 2 min. 
72''G for 10 minutes. Then 35 cycles of 95°G for 30s, SS'G for 45s, 72°C for 
90s, then a 5 min extension at 72''G. A second round of PGR was performed in a 
12.5 pi reaction using 0.5pl of sample from the first round of PGR and 10 pmoles 
primers UE1 and d-anchor, (specific to the 5' end of the anchor primer). 30 
cycles of PGR were performed at 95"'C for 30s, 65®G for 30s, and 72°C for 60s, 
followed by a 5 min. extension at 72°G. 
Results 
The mrp/plf3 gene requires an enhancer in vivo 
The mrp/p/f promoters from -1100 to + 64 have been used previously to drive 
growth factor or serum regulated expression of CAT reporter genes in 
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transfected cells (Linzerand Mordacq. 1987; Mohldeen etal., 1999). To analyze 
activity of the mrp3 regulatory elements in vivo, a hybrid intron composed of the 
adenovirus splice donor and IgG splice acceptor (Huang and Gorman. 1990) and 
the lacZ gene were inserted between 1514 basepairs of 5' m/p3 flanking 
sequence (-1450 to +64), and the fifth exon of mrp3 (+660 to the poly A signal at 
+790) with approximately 3600 basepairs of 3' flanking sequence downstream to 
produce the plasmid construct -1450mrp3/sis/lac/3.6. These transgenes 
produced no detectable reporter gene activity when integrated into the genome 
of mid-gestational embryos (Table 1). yet are active in transient lipofection 
mediated transfections of cultured COS cells, BNL cells, or trophoblastic giant 
cells (not shown). It was thus possible that the transgene was t>eing inactivated 
when integrated into chromatin, and might be missing an enhancer needed to 
overcome inhibitory chromatin structure. To test the hypothesis that this 
construct could be active when integrated into chromatin in vivo when a strong 
enhancer was present, the -1450mrp3/sislac/3.6 construct was co-injected with a 
|3-actin driven expression cassette containing 5kb of 5' flanking sequence and 
800 basepairs 3' untranslated sequence. This cassette expresses P-
galactosidase ubiquitously in mid-gestation embyos (not shown). The lacZ gene 
was replaced in this construct with the plf1 cDNA. Co-injection with the 
ubiquitously active p-actin cassette resulted in detectable 0-galactosidase activity 
in 2 out of 5 transgenic embryos, but expression was ubiquitous in one 
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embryo/placenta, and scattered throughout many different ceil types in the other. 
This suggests that co-integration with an active gene allowed the previously 
inactive mrp3 transgene to be active. Further work was not done however to rule 
out the effects of pifl overexpression, the possibility of recombination between 
sequences present in both transgenes, or the possibibity that transcription from 
the actin promoter was reading through to the mrp3 gene and splicing was 
occurring between the actin intron and the hybrid intron in the lac Z gene. To 
further investigate the effect of a strong enhancer upon mrp3 promoter activity, 
but to avoid the complications discussed above, the hCMV immediate early 
enhancer was added to the 5' end of the construct, so that only the mrp3 
promoter would be available to the enhancer (CMV/-1450mrp3/sislac/3.6). When 
tested in el 1 transgenic embryos, the spatial expression of this construct 
paralleled endogenous expression of mrp/plfs, showing 3-galactosidase activity 
only in the trophoblastic giant cells of the placenta (Fig 1 and table 1). At el 3, 
three of four embryos displayed p-galactosidase activity in the embryo proper, 
but still displayed giant cell specific expression in the placenta (not shown). In 
most of the transgenic embryos, expression was not evident in the majority of 
giant cells, but appeared in a variegated pattem, and at times was limited to only 
a few giant cells. In one of two lines produced with this construct, the transgene 
also expressed in adult mice in a pattem similar to endogenous mrp3, 
demonstrating P-galactosidase activity induced during cutaneous wound healing 
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and during the hair follicle cycle (Fassett; submitted). Ectopic expression was 
observed however in the liver, but was absent from kidneys, lungs, stomach, 
spleen, heart, and testes. The second transgenic line prepared with this 
construct demonstrated lower levels of 3-galactoskiase activity but expression 
was still detectable in tail wounds. F1 offspring of the transgenic adults also 
expressed the transgene in giant cells, but in a small number of giant cells and in 
a variegated pattem, similar to the majority of the FO transgenics. The transgene 
was also expressed in the decidua of pregnant female transgenic mice at high 
levels (not shown). At this time, it is not clear whether this represents ectopic 
expression or specific expression, as mrp/jj/fRNA is detectable by Northern blot 
from this tissue (Linzer etai, 1985), and protein is also evident in the decidua 
using immunohistochemistry (unpublished), but in situ hybridization failed to 
detect the signal in the decidua relative to extremely high levels of giant 
cell expression (Lee etai, 1988). 
Mrp3 5' and 3' flanking sequences mediate tissue specific expression 
under the influence of the CRffV enhancer 
The CMV enhancer is active in numerous tissues of the midgestational 
embryo and the adult mouse, but not in the midgestational placenta (Baskar et 
al., 1996a; Baskar et al., 1996b. Koedood et al., 1995). Our results showing that 
inclusion of the CMV enhancer upstream of the mrp3 promoter sequences 
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results in specific expression in the placental giant cells suggests that elements 
within the mrp3 promoter and surrounding sequences are able to repress 
expression in most tissues and/or these elements interact with the CMV 
enhancer to induce transgene expression specifically in the trophoblastic giant 
cells. 
To identify sequences that may act by either suppressing non-specific 
expression or inducing tissue specific expression, a series of deletion mutants 
were examined either in transfected cells or in transgenic embryos. Deletion of 
3kb of mrp3 sequences from the 3' end (CMV/1514mrp3/sis/gal/0.6U) still 
resulted in giant cell expression, but caused a higher level of non-specific 
expression in el 1 transgenic embryos. The expression patterns of P-
galactosidase activity in these embryos and placentae varied dramatically, 
suggesting that the site of integration might also effect the activity of the 
transgene (table 1). In two lines of transgenic mice containing this construct, 
embryonic expression also varied, with one line expressing in both the giant cells 
and the embryo proper, and the other demonstrating very little expression in the 
embryo or placenta. 
To investigate the role of the mrp3 5' flanking sequences in tissue specific 
expression, a further deletion of the 5' end of the mrp3 gene was made, so that 
only 113 bp of mrp3 upstream sequence remained (-49 to +64). The resulting 
animals displayed more aberrant expression and less staining in giant cells than 
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animals expressing from the longer mrp3 promoter sequences, suggesting giant 
cell specificity is also regulated by elements between -49 and -1450. Four out of 
the 6 transgenic embryos produced with this construct were less developed than 
12 non-transgenic animals produced in the same experiment. A single line was 
produced with this construct, in which high level expression was evident in all 
embryonic and adult tissues examined. Figure 2 demonstrates that while the full 
length mrp3 transgene is only expressed in response to wound healing or during 
the hair follicle cycle, the minimal (-49 bp) mrp3 construct was expressed 
throughout all tissue layers of the tall. This construct also expressed 
3-galactosidase activity by the 16 cell stage of development, while the full length 
construct appears inactive at this time point (data not shown). 
Hybrid intron not efficiently spliced in transgenic placentae 
In some cases, one half of each placenta of the FO embryos was saved for 
RNA or DNA analysis. RT-PCR was performed on samples using primers that 
amplify from the 5' untranslated region of the mrp3 gene across the hybrid intron 
to the lacZ gene. In most transgenic samples lacking an enhancer, no lacZ RNA 
was detected, however, in two that were, very little splicing of the transgene was 
observed. As well, splicing was inefficient in a placenta from a embryo produced 
using the -1450sislac3600 construct co-injected with B-actin cassette, and also 
from a transgenic placental sample containing the cmv/-1450sislc600 transgene. 
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(Fig 3). This intron is completely spliced when under control of the SV40 
promoter in transfected cultured cells (not shown). 
Tissue/cell specific splicing of hybrid intron 
To further investigate splicing of the transgene, we examined other conditions 
where mrp3 expression is induced. Recently we have detected mrp3 expression 
in the hair follicles and also during wound healing and in isolated keratinocytes 
(Fassett and Nilsen-Hamilton, submitted). In the skin of a 13 day old mouse, 
which contained numerous |3-galactosidase positive hair follicles, there was a 
higher level of spliced relative to unspliced transgene, than in the heart of the 
same mouse, and where transgene expression is not detectable (figure 4). In 
isolated 4-day old mouse keratinocytes, the cell type that expresses mrp3 in the 
skin, there was a much higher level of splicing than in whole skin samples from 
adults of the same line. KGF, which induces mrpS expression in keratinocytes, 
had little effect on the level of splicing, suggesting that tissue specific splicing is a 
function of the cell type and not a consequence of an extemal signal such as 
from a growth factor. 
RNA from a skin wound, where the transgene is induced, appeared to be 
spliced at a higher relative level than skin from a non-wounded transgenic mouse 
of the same line. Another band smaller than the predicted size of spliced 
transgene also appeared which has not t>een characterized. Skin from the line 
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of transgenic mouse containing the minimal promoter downstream of the CMV 
enhancer (CMV/(-49)sisl/lac/0.6U) however, contained mostly spliced transgene 
transcripts. Together, these results suggest that splicing levels are higher in the 
cells or tissues that express mrp3 (keratinocytes). Other cell types t)esides 
keratinocytes within the whole skin or in tissues such as the heart, which do not 
express mrp3, may contribute to a higher level of unspliced transcripts within the 
total RNA population. Furthermore, the complete splicing of the transcribed 
transgene containing the minimal mrp3 promoter suggests that sequences 
upstream of position -49 may contribute to a lower level of splicing and 
transgene expression in tissues that don't express mrpS. 
One mechanism by which upstream 5' flanking sequences of the mrp3 gene 
could effect splicing is by acting as altemate transcript initiation sites that result 
in the production of nonsense transcripts. Nonsense mutations have been shown 
to inhibit splicing (Aoufouchi etal., 1996), or result in altered nuclear stability or 
processing (Hentze and Kulozik, 1999; Maquat, 1995). Because the 5' region of 
the mrp3 gene appears to effect splicing of a heterologous intron, and the 
endogenous plf1 transcript level is regulated by post-transcriptional RNA stability 
and RNA processing in 3T3 cells, we analyzed 3T3 cells, placentae and embryo 
for the presence of upstream nonsense transcript producing promoters. 
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Upstream alternative transcript initiation sites in endogenous mip/plf 
genes are diffferentiy processed 
RACE was used to map the transcript initiation sites in el 1 embryo nuclei and 
unstimulated 3T3 nucleii, where expression is absent or low, or in e11 
placentae or FGF stimulated 3T3 nucleii in which expression is high. 
Initial reverse transcription was performed using primers that hybridize to intron I 
(UI1) or exon III (UE3), while the final round of amplification used sequential 
primers which hybridize to exon I so that the transcription start site could be 
mapped for unspliced versus spliced transcripts in these conditions. E11 embryo 
nuclei did not produce any detectable transcript using either primer. Using either 
initial primer, the majority of the PCR products of the placenta demonstrated the 
size of fragment predicted from amplication of a product between the poly Gl 
race primer, the normal transcriptional start site and the UE1 primer. By 
contrast, the 3T3 cell transcripts contained a larger sized PCR product when 
using UE3 compared with the UI1 for reverse transcription. The larger sized 
product appeared to increase in the absence of FGF, but was absent from 
samples reverse transcribed with primer UI1 (Fig 5a). The longer product 
produced from 3T3 mRNA was was sequenced and found to start 142 bp 
upstream of the previously described start site for plf1 (Linzer and Wilder, 1987). 
To further investigate the processing of transcripts initiating from upstream 
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promoters, RT-PCR was performed on RNA samples using primers specific for 
intron 4 or exon 5, in combination with primers specific for either -*-42 to -*-63, or -
82 to -62 (Fig. 6). Amplification of cONAs from within -*-42 of the normal start site 
to 305 bp of intron 4, or -<-776 in exon 5. was observed in stimulated or 
unstimulated 3T3 cell nucleii and total placental RNA. cONA derived from 
upstream initiation sites which contained intron 4 however, was only detected In 
the unstimulated 3T3 cells (Fig. 5b). In COS cells, a full length mqo3 gene 
containing all four introns, and under the control of the CMV(mrp3/-1514) 
enhancer sequence produced fully spliced transcripts derived from sites 
upstream of -82 or -i-63, but little incompletely processed transcript was 
observed. To further investigate the processing of transcripts beginning at 
endogenous upstream promoters, RT-PCR was performed on cytoplasmic or 
nuclear RNA isolated from bFGF stimulated or unstimulated 3T3 cells. As 
demonstrated in figure 5c, the cytoplasmic levels of transcripts derived from 
upstream start sites appears greater than the nuclear levels, whereas primers 
amplifying transcripts from the normal and upstream start sites appear at similar 
levels In the cytoplasm, suggesting that the upstream transcripts are either less 
stable In the nucleus or are transported to the cytoplasm more rapidly. 
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Upstream sequences repress functional expression and produce 
transcripts which are poorly spliced 
To determine if upstream alternate promoter containing sequences could act 
as transcriptional repressors, two constructs that contained the CMV enhancer 
upstream of -130, or -231 were tested in transient transfected COS cells. The 
activities and splicing of these constructs as well as the CMV(-49) and the CMV(-
1514) constructs were compared by measuring the levels of lacZ RNA compared 
to a cotransfected SV40 driven CAT vector (pSV40sis CAT). Both the 
CMV(m/p3) lacZ constructs, and the (pSV40sisCAT construct contained the 
same heterologous hybrid intron, so levels of lacZ RNA relative to cat RNA may 
be compared between the constructs using RT-PCR and allowing the CAT and 
lacZ DNA amplicons to compete for annealing of the common primer. The 
results in (Fig. 6) demonstrate that there was a higher level of LacZ RNA in the 
cultures transfected with the CMV(-49) and CMV(-130) construct relative to cat 
RNA than from transfections using the CMV(-1514) and CMV(-230). 
Significantly, the level of spliced to unspliced transcripts appeared higher in the 
CMV(-49) and CMV(-130) construct than the CMV(-1614) or CMV(-230) 
constructs (fig. 6). This suggests that upstream regions of the mrp3 gene, 
particularly between -130 and -230 contain repressors of activation by the CMV 
enhancer, and may inhibit splicing of the heterologous hybrid intron, or 
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specifically cause degradation of spliced lacZ RNA. It is also evident that the 
hybrid intron is completely spliced when placed downstream of the SV40 
promoter in the SV40sisCAT construct, suggesting that the low level of spliced 
product is caused by the mrp3 5' flanking sequence and not by the intron itself. 
As well, if lacZ replaces the cat gene downstream of the hybrid intron 
(SV40sisLAC), the intron is also completely spliced.(lane 5) (Note.The spliced 
lacZ fragment is larger in this case because it is has an extended 5' untranslated 
region between the intron and the lacZ cosing region which adds approximately 
200 basepairs.) 
Analysis by RT-PCR demonstrates that transcripts originating upstream of the 
normal start site (-*-64) contain a higher ratio of unspliced to spliced intron than 
transcripts amplified from within the normal transcription start site, (fig 7). This 
suggests that upstream start sites are greater contributors to the total amount of 
unspliced RNA and supports the hypothesis that the transgene transcripts 
initiated at the correct promoter are more effectively spliced. Curiously, the 
construct containing the CMV/-130 mrp3 promoter produced mostly spliced RNA, 
but transcripts which began at or 5' of -130 were not spliced efficiently. 
Discussion 
The results presented illustrate two interesting aspects of gene regulation. 
First, tissue specific gene expression from an otherwise weak promoter is 
demonstrated in the presence of a strong, heterologous and somewhat 
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constitutive enhancer. Second, the 5' flanking sequences of the mrp3 gene can 
effect splicing in a tissue or cell specific fashion, likely by modulating usage of 
either productive promoters or non-productive nonsense promoters. 
The finding that 1514 bp of 5' flanking sequence of the mrp3 gene and 3.6 kb 
of 3' flanking sequence was not sufficient to express detectable reporter gene 
activity in transgenic mice, suggested that other sequences were necessary for 
higher level expression. These missing sequences were in part substituted for 
by the heterologous hCMV IE enhancer. Because the hCMV IE enhancer can 
direct expression to the el 1 embryo proper from it's own minimal promoter 
(Baskar et a/., 1996a; Koedood et a!., 1995) and in our constructs this occurs in 
the absence of 3' and 5' fn/p3 sequences, it suggests that mrp3 sequences can 
repress activity of the CMV enhancer upon the mrp3 promoter in the absence of 
tissue specific factors. The observation that the spatial expression of transgenes 
from the constructs lacking the 3' 3kb varied in each embryo examined suggests 
that downstream sequences possibly insulate the mrp3 gene from the effects of 
surrounding sequences. 
At this time It cannot be concluded whether repression occurs from specific 
elements In the flanking mrp3 sequences, or by increasing the distance of the 
CMV enhancer, decreasing the chance of interaction with the proximal elements 
of the mrp3 promoter, or from a combination of both of these effects. Proximity 
to the CMV enhancer has been shown to affect the level of expression from a 
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heterologous promoter (Kuhl etal., 1987). 
It is likely that chromatin structure plays a large role in regulation of the mrp3 
transgene and could be involved in regulation of the endogenous mqj/plf genes 
as well. This is suggested by the lack of detectable p-galactosidase expression 
from the mqj3 promoter in absence of an enhancer, the variegated expression 
pattem of the CMV/mrp3 transgene. and the widely varied pattern of expression 
observed between different FO embryos in the transgenes containing deletions. 
Sensitivity to chromatin structure is also indicated by the observation that 
regulation by bFGF was only observed in 3T3 cells stably transfected with mrp3 
promoter constructs (Mohideen et al., 1999). 
Position effect variegation has been reported for expression of transgenes that 
are inserted into inactive chromatin (Boyerefa/., 1997; Robertson etal., 1995). 
If the transgene is inhibited by chromatin structure, and because the CMV 
enhancer is not reported to t>e active in the placenta of midgestation embryos, it 
is possible that elements of the mrpS gene interact with the CMV enhancer in a 
tissue specific fashion to increase the probability of overcoming inhibitory 
chromatin. Activation by an enhancer requires both the elements within the 
enhancer and an active promoter with which to interact. Removal of elements 
upstream of -49 from the mrp3 5' region produced p-galactosidase expression 
patterns which differed significantly from the expression pattem of the full length 
construct and the endogenous pattem of expression. Notably, with the exception 
of the single line of cmv-49/sis/lac/600 mice, expression in embryos did not 
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appear to be particularly strong, just more widespread and still variegated. In 
transient transfection, this construct appeared to express at much higher levels 
than the construct containing the -1450 sequence. Again this is suggestive of an 
interaction tietween flanking sequences of the mrp3 gene and the CMV 
enhancer to overcome chromatin structure, particularly in the giant cells. 
Elements that may be involved in regulating activity of the mrp3 promoter 
particularly in the trophoblastic giant cells could include GATA sites, a c-ets-2 
element, or AP-2 element, all of which are found in the proximal mrp3 promoter 
and which bind proteins that have been demonstrated to be important for 
expression of placental specific genes or placental development (Ma etal., 1997; 
Shi and Kellems, 1998; Yamamoto et al., 1998). It is likely that a very strong 
enhancer or locus control region also regulates the endogenous mrp/plf genes, 
because endogenous levels of m/p/p/f expression are extremely high in the giant 
ceils during gestation. The related human growth hormone/human placental 
lactogen gene cluster, which is -66 kb and contains five closely related genes, is 
regulated by a placental specific enhancer at the 3' end (Jacquemin et al., 1994) 
and a multi-component locus control region at the 5' end (Jones et al., 1995). 
As well, the enhancer elements within the 3' end of the human placental 
lactogens act as silencers of pituitary expression by the placental genes (Jiang 
and Eberhardt, 1997). Because mrp/plfs are closely related to the growth 
hormone and placental lactogen genes, it is possible that mrp/plfs are also 
regulated in a similar manner. 
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Post-transcriptional regulation of pifl gene expression has been described in 
3T3 cells and in primary mouse embryo fibroblasts (MEF) in which primary 
transcripts were shown to be incompletely processed or degraded in the nucleus. 
Stimulation of 3T3 cells by bFGF or serum resulted in an increase in mRNA 
levels but no change in the rate of transcription (Linzer and Wilder, 1987; 
Nilsen-Hamilton etai, 1987 Mohideen; 1995). Similarly, immortalization of 
MEFs resulted in increased expression o1 pff1 in the absence of increased rates 
of transcription (Edwards eta!., 1987; Malyankar eta!., 1996). In FGF-stimulated 
3T3 cells, increased levels of pifl mRNA could not be ascribed to a decreased 
rate of degradation (Mohideen; 1995). The mechanisms of post-transcriptional 
control of p/f1 gene expression are not well understood, but appear to be at the 
level of nuclear stability and processing of the primary transcript (Edwards et a!., 
1987; Malyankar ef a/., 1994; Malyankar efaA, 1996; Mohideen, 1995. 
From the studies described here, the 5' and 3' sequences of the mrp/plf3 gene 
appear to be Important for regulating tissue specific expression in the presence 
of a constitutive CMV enhancer. However, the evidence suggests that the 5' 
flanking sequence of the mrp3 gene also regulates splicing of the transgene in a 
tissue specific fashion. This conclusion is proposed because, although the 
hybrid intron used in these studies has been demonstrated to be efflciently 
processed in numerous tissues (Choi et al., 1991), the intron was only found in 
the entirely spliced form in the absence of the majority of the 5' flanking 
sequences of the mrp3 transgene. Because the extent of splicing was further 
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diminished in transcripts that began 5' of the normal start site, it is likely that the 
majority of unspliced transcripts were derived from upstream promoters. 
It is possible that tissue specific transcriptional regulation and splicing of the 
mrp3 gene is mediated in part by competition between different promoters within 
the 5' flanking sequences. Competition t>etween two promoters for activation by 
one enhancer has been demonstrated in transient transfections of the p- and, e-
globin promoters in the presence of the P-globin enhancer (Choi and Engel, 
1988). Also, the active even skipped gene promoter acts as a boundary that 
prevents activation of a second even-skipped promoter in the presence of the 
trithorax like gene product (Ohtsuki and Levine, 1998). It is thus possible that, in 
the absence of tissue specific factors, ubiquitous transactivators bound to the 
CMV enhancer (or an as yet unidentified enhancer associated with the 
endogenous genes) could recruit RNA polymerase or relieve repressive 
chromatin structure only in relation to upstream promoters. The initiation of 
transcription at -142 is in agreement with the identification of a minor 
transcription start site identified by Linzer ( Linzer and Wilder; 1987), and could 
be due to a TATA binding sequence identified at -170 to -162 or a TFIId binding 
element at -161. Transcripts initiated at or upstream of -142 would contain at 
least two translational start codons (ATG) that are followed by nonsense codons 
prior to the first intron. These are conditions that cause nonsense mediated 
nuclear RNA degradation (Hentze and Kulozik, 1999; Lim et al., 1992; Maquat, 
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1995; Urlaub et al., 1989). Thus the relative lack of spliced transgene transcripts 
derived from upstreann promoters may be due to recognition by a RNA 
surveillance mechanism (Hentze and Kulozik, 1999) that identifies and degrades 
transcripts that contain nonsense codons followed by introns (Maquat, 1995; 
Zhang et al., 1998a; Zhang et al., 1998b). The presence of nonsense codons 
upstream of an intron has also been demonstrated to prevent splicing (Aoufouchi 
etaf., 1996: Naegerefa/., 1992). 
It is also possible that RNA Poll! is not phosphorylated on the carboxy terminal 
tail when it initiates transcription from these altemate upstream promoters so 
splicing is inefficient (Misteli and Spector, 1999; Steinmetz, 1997). 
The low ratio of spliced to unspliced hybrid intron from the mrp3 promoter 
reporter constructs appears to contrast with results obtained with endogenous 
mrp/p/f transcripts. The sequence differences between the hybrid intron and the 
endogenous introns could cause the primary transcripts to be processed 
differently. As well, the difference in the number of introns (4 in endogenous 
mrp/plf and 1 in the transgene) could effect processing, it is possible that in 
upstream nonsense transcripts, intron I of the endogenous mq^pHs is also not 
being spliced, similar to the hybrid intron, but introns 2 through 4 in the 
endogenous genes mediate the decay of these transcripts. This might explain 
why only spliced RNAs demonstrated the upstream initiation site using RACE. 
In conclusion, we have demonstrated that mrp3 flanking sequences may 
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direct tissue specific expression, but only under the additional influence of a 
heterologous enhancer. Furthermore, we demonstrate that the 5' flanking 
sequences of the /n/p3 gene affect the number of spliced transgene transcripts 
in a tissue specific fashion, likely by selection of alternate upstream start sites. 
Because as much as 2/3 of all exonic RNA remains or is degraded in the nucleus 
(Jackson et ai, 2000), the results demonstrated here present a provocative 
model of how transcriptional start site regulation could tie a dominant but cryptic 
(due to nuclear degradation or inefficient processing) mechanism of gene 
regulation in mammalian cells. 
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Figures 
Figure legends 
Figure 1. The CMV/-1450mrp3/8is/lacZ/3.6 transgene is specifically 
expressed in the trophoblastic giant cells.fO e11 or el 3 embryo and 
placentae were dissected from the uterus, fixed, and stained ovemight for 3-
galactosidase activity. El 1 P-galactosidase activity is demonstrated in the 
trophoblastic giant cell layer(TG), and is absent from the embryo, or other layers 
of the placenta(D=decidual; SG^spongiotrophoblast). 
Figure 2. Removal of 5' and 3' flanking sequences causes aberrent 
expression of CMV/mrp3/constructs. Wounds were produced in CMV/-
1450mrp3/sis/lac/3.6(a) or CMV/-49mrp3/sis/lac/0.6(b) transgenic mice by 
snipping approximately 2mm from the tip of the tail. Mice were sacrificed 3 days 
later and the wounds were stained for P-galactosidase activity. 
Figure 3. Limited splicing of transgenic hybrid intron . 1/2 of 3 transgenic 
placentae from either -1450mrp3/sis/lac/3.6(lane1) or from -
1450mrp3/sis/lac/3600 co-injected with a B-actin promoter/3' end cassette(lane2) 
or a CMV/-1450/sislac/600 construct(iane 3) were used for RT-PCR using 
primers going upstream from the lacZ gene(ULAC) and downstream from the 5' 
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untranslated region of the nnrp3 transgene(d4263). Little spliced product(S) was 
observed relative to unspliced(U). Lanes 3.4. and 5, are from the same RNA 
samples in the absence of reverse transcriptase. 
Figure 4. Tissue and ceil specific splicing of the transgenic hybrid intron 
RT-PCR using primers which amplify between the mrp3 5' untranslated 
region(d4263) and the lacZ gene(ULAC), was performed on the skin(lanel) and 
the heart of a day13 mouse pup(lane 2), as well as isolated keratinocytes 
stimulated or not stimulated with KGF(lanes 3 and 4), wounded or non-wounded 
mouse skin(lane 5 and 6). or non-wounded skin from a line of transgenic mice 
containing the CMV/-49mrp3/sis/lac/.6 construct(lane 7). Lanes 8-14 are the 
same samples as lanes 3-7 but in the absence of reverse transcriptase. After 
PGR, the products were run on a 2% agarose gel and photographed under UV 
illumination. U represents unspliced PGR product and S represents spliced PGR 
product. The intermediate band between spliced and unspliced products is a 
hybrid of DNA strands from spliced or unspliced cDNAs which hybridized during 
PGR. Shown above the lanes is the ratio of spliced to unspliced product as 
measured by scanning densitometry of the film. 
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Figure 5. Alternate upstream mip/p/f transcripts are present and are 
differently post-transcriptionally regulated, (a) Rapid amplification of cDNA 
Ends(RACE) was perfomned on e11 embryo, total ell placental RNA, or 17hr. 
FGF stimulated or unstimulated 3t3 cell nuclear RNA, using primers 
complementary to intron I or exon III sequences for reverse transcription, 
followed by two rounds of amplification using a primer complementary to exon 1 
and primers specific for the C-tail. The larger sized band observed in the 
absence of FGF stimulation was sequenced and corresponded to a transcription 
start site 142 base pairs 5' of the placental start site.(b) Transcripts beginning 
from upstream start sites of endogenous mrp/plf genes are identified in 3t3 
nuclei with and without FGF, in total placental RNA, and in total RNA from cos 
cells transfected with a full length mrp3 gene containing all four introns and 
under control of -1450 mrp3 and CMV. (c) RNAs derived from upstream start 
sites appear to be more prevalent in the cytoplasm than the nucleus of 3t3 cells. 
Lanes 1-4 3T3 are nuclear RNA from FGF stimulated(1, 2), or unstimulated(3, 
4). Lanes 5-8 are cytoplasmic RNAfrom FGF stimulated(5, 6), or unstimulated(7, 
8). Lanes 9 and 10 are from placental RNA. Odd lanes are using primers which 
amplify from +42 to exon 3. Even lanes use primers which amplify from -82 to 
exon 3. 
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Figure 6. 5* mrp3 sequences decrease expression and cause lower relative 
levels of splicing. Constructs containing either-49, -130, -230, or-1450 of 
mrp3 sequence downstream of the hCMV enhancer were transfected into cos-1 
ceils, and RT-PCR was performed as described using primers recognizing the 5' 
end of the hybrid intron, or either the cat or lacZ gene. SL or UL represents 
spliced or unspiiced hybrid intron firom iacZ constructs respectively. SC or UC 
represent spliced or unspiiced hybrid intron from Svsiscat constructs. 
Figure 7. Lower ratios of spliced:unspiiced transcripts produced from 
upstream promoters. 
RT-PCR ws performed on RNAs from figure 6 using primers that recognize 
transcripts from different regions of the 5' flanking sequence of mrp3 and a lacZ 
specific primer. 
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Table 1. Transgene expression from mrp3/sis/lacZ constructs is not detectable in 
transgenic embryos or placentae in the absence of a strong enhancer. 
Transgenic embryos were identified by PGR on a portion of the yolk sac. 
Construct day #tx ectopic G.C.stain G.C. spec, stain 
-1450mrp3/sis/lac/.6 11. 5 0/5 0/5 0/5 
-1450mrp3/sis/lac/3.6 11 12 0/12 0/12 0/12 
cmv/-1450nirp3/sis/lac/.6 11 7 5/7 4/7 1/7 
cmv/-1450mrp3/sis/lac/3.6 11 6 0/6 5/6 5/6 
cmv/-1450mrp3/sis/lac/3.6 12 2 1/2 2/2 1/2 
cmv/-1450mrp3/sis/lac/3.6 13 3 2/3 3/3 1/3 
cmv/-48mxp3/sis/lac/.6 11 9 7/9 4/9 0/9 
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CHAPTER 6: CONCLUSION 
The aim of the research presented here was to gain a better 
understanding of the spatial and temporal expression pattem of each of the 
mrp/plf gene family members in vivo. Research was also performed with the 
goal of understanding the mechanism by which mrp3 is expressed in a tissue 
specific fashion. In pursuit of these goals, as detailed in the previous three 
chapters, a number of findings have been made that will contribute to the 
understanding of m/p/p/f regulation in the mouse. The significance of these 
results as they relate to the specific aims of this project and current 
understanding in the field will be addressed below, as well as recommendations 
for studies following this work. 
Tissue and temporal specific expression of different m/p/p/f genes 
Results presented in this thesis demonstrate for the first time that 
expression of three mrp/plfs {mrp3, plf1, and a newly identified mrp/plf :mrp4) is 
differently regulated in tissue specific patterns in the adult mouse, and also 
temporally in the placenta. MqpS is shown to be the most abundant mrp/plf \n the 
placenta and is also the predominant form expressed by keratinocytes during 
cutaneous wound repair. Plf1 is expressed at higher relative levels during eariy 
gestation and is also the predominant m/p/p/f expressed in the stomach and 
small intestine. Mrp4 is a newly identified mrp/plf thai is expressed at higher 
levels slightly later in gestation, and that is also the predominant mrp/plf 
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expressed in the ear and tail of adult mice. 
Extra-placental expression of mrp/plf genes 
What is the significance of multiple mqa/pHs expressed in particular tissue 
and temporal specific patterns? The identification of mrp/plfs in non-placental 
tissues suggests that these genes may have functions outside of 
pregnancyPreviously identified as a uterine growth factor, it is possible that 
mrp/pifs have a similar role in extra placental tissues. Cell proliferation occurs 
during wound healing, the hair follicle cycle, and during the constant replacement 
of the lining of the gastro-intestinal tract. MRP/PLFs could play a role in the 
proliferation of cells in these locations, similar to one of the roles it plays during 
gestation. Another function could include angiogenesis, which is also a 
described function of placental MRP/PLFs, and which would likely be necessary 
in order for growing or regenerating tissues to acquire a blood supply. 
Angiogenesis is a vital component of wound healing (Klein et al., 1999), and is 
also increased around the growing hair follicle (Mecklenburg et al., 2000), both 
sites where MRP/PLFs were identified. It is also possible that MRP/PLFs could 
act as local competitors for interaction with the IGF ll/Mannose 6-Phosphate 
receptor. It has been demonstrated that activation of the latent form of TGF  ^
occurs through a mannose 6-phosphate dependent binding to the mannose-6-
phosphate receptor and cleavage by urokinase (Ghahary et al., 2000; Godar et 
al., 1999). MRP/PLF-expressing cells could thereby locally prevent the effects of 
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TGFg—by competing for binding to the mannose-6 phosphate receptor to prevent 
TGF3 -activation. MRP/PLF could also act intracellularty to inhibit differentiation 
of cells that are needed to proliferate, as in mouse myoblasts. (Muscat et al., 
1991; Wilder and Linzer, 1989) MRP4 is distinct from the other mrp/plfe in that it 
is less glycosylated and is missing a small helical region in the C terminus that is 
found on the other MRP/PLFs. Therefore, it is possible that MRP4 may have a 
different function than MRP3 or PLF1. It will be important in this regard to find 
out if MRP4 contains mannose-6-phosphate (M-6-P) residues and binds to the 
M-6-P receptor and/or interacts with the mrp receptor identified in uterine cells 
(Nelson et al., 1995). The identification of predominantly mrp4 expression in hair 
follicles of tails and the ears of mice, two relatively hairless areas, and the 
expression of mostly mrp3 in the hair follicles of the backskin or during wound 
healing also encourages speculation that these proteins may have different 
functions specifically in the skin and possibly with relation to hair growth. 
Growth hormone and prolactin are expressed in tissues other than the 
pituitary, however, there have been few reports demonstrating extra-placental 
expression of the placental memt>ers of the PRLyGH family. Because MRP/PLFs 
have not been demonstrated to bind the prolactin or growth hormone receptors, 
it may not be useful to suggest functions of extra-placental MRP/PLF expression 
based upon functions of extrapituitary prolactin expression. Suggestions as to 
the functions of MRP/PLF in extra-placental tissue will likely come from more 
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thorough analysis of MRP/PLF receptor localization. Immunohistochemistry has 
demonstrated MRP/PLF protein in the tissues expressing mrp/plfmRNAs, and it 
is likely, but not definite, that the cells staining positively for MRP/PLF protein are 
expressing MRP/PLF proteins. To better determine which cells are producing 
specific mrp/plfs and which cells are binding it-the protein will require in situ 
hybridization or in srtu RT-PCRi-comblned with analysis of MRP/PLF binding 
sites in or near these tissues. In situ RT-PCR would t>e especially useful, 
because specific mrp/plf forms could be identified by choosing primers that only 
recognize one form, whereas in situ hybridization would not distinguish between 
different m/p/p/f types. Identification of MRP/PLF binding sites, and 
determination of whether M-6-P is involved in binding will be very important for 
the identification of a function for extra-placental MRP/PLF. 
Functional knockouts of m/p/p/f expression may also be revealing. It 
would be difficult however, to knockout all mrp/plf expression using homologous 
recombination, because there are at least four highly homologous genes. 
However, because each mrp/plf \s expressed with a different tissue distribution, it 
may not be necessary to knockout all of the mrp/plf genes. It may be more 
revealing to knockout individual mrp/plf genes and determine how each 
contributes to the physiology of the mouse. Another option, made possible by the 
high homology between mrp/plfs, is that all the mrp/plf rr\Rt4As may be targeted 
at once for antisense or ribozyme mediated destruction. As the technology for 
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producing effective ribozymes continues to improve, it may be possible to 
effectively destroy mrp/plf messages in specific tissues or at specific times using 
tissue specific or inducible promoters to express a ribozyme which recognizes all 
the forms of mrp/plf. In fact, numerous promoters have t)een characterized that 
express transgenes in specific tissues, including the outer root sheath of hair 
follicles (Pena et al., 1999; Scler et al., 1996), keratinocytes at the edge of 
healing skin wounds (Mohan et al., 1998; Munaut et al., 1999), tail skin (Werner 
et al., 1993), and trophoblastic giant cells (Shi et al., 1997). Because of its very 
high expression in the placenta, to reduce mqj/p/fleyels in the placenta using 
antlsense or ribozymes would likely require a very strong promoter. 
In exploring the function(s) of MRP/PLFs, it also might be informative to 
over express a particular MRP/PLF in a specific tissue and determine if there is a 
phenotype. For instance, mrp4 could be over-expressed in the backskin of mice, 
or mrp3 could be directed to the tail and ears. These studies could help to 
determine if the natural pattern of segregation of these forms serves a purpose 
or is just a result of coincidental accumulation of transcription factors that 
activate a specific form of mrp/plf expression. 
MRP/PLF expression in the placenta 
The functions suggested for MRP/PLF in the placenta and the uterus 
include angiogenesis and stimulation of uterine growth respectively (Jackson et 
al., 1994; Nelson et al.. 1995). How does this relate to the temporal expression 
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patterns of different mrp/pHs in the placenta during gestation? The most notable 
characteristic of differential mq /^plf expression that may relate to function, is the 
day 12 peak of mrp4 expression. This is likely the source of a lower MW mrp 
identified by Western blot that is found at the highest levels on day 13 (Fang et 
a!., 1999). If MRP4 has a similar function to the other MRP/PLF forms, this 
expression pattem could contrast with the current model proposed by Linzer, in 
which MRP/PLF angiogenic activity decreases at the same time that expression 
of a angiogenesis inhibitor called Proliferin Related Protein (PRP), increases in 
order to shut down neovascularization and restrict invasiveness of the placenta 
(Jackson et al., 1994; Linzer and Fisher, 1999). Interestingly, PRP (Colosi et al., 
1988) and Mrp4 are expressed in the placenta at the same time. 
Unlike the more highly glycosylated forms of MRP/PLFs, MRP4 is not 
found in the amniotic fluid. This observation suggests that MRP4 is either rapidly 
degraded, bound to a receptor, or is not effectively transported to the fetus. 
However, the precise location of mrp4 expression within the placenta and how it 
relates spatially to PRP secreting cells is not clear. So it is still possible that 
MRP4 and PRP have very local but opposite effects. It is also possible that the 
lack of M-6-P residues prevents MRP4 angiogenic activity or even causes MRP4 
to act similarity to PRP, as an angiogenesis inhibitor. 
Identifying a function for different temporal expression patterns for MRP4 
and the other MRP/PLF fonns will depend upon the demonstration of binding 
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activity for MRP4, stimulation of receptors by the different MRP/PLF proteins, as 
well as the localization of these receptors in specific tissues and cell types. It 
would also be of interest to perform in situ RT-PCR with mrp4'Spedfic primers in 
order to determine if this gene is expressed in the same cells as the other 
mrp/plfs. Specific expression of mrp/p/f RNA in the giant cells have been 
demonstrated for day 10 placentae by in situ hybridization (Lee et al., 1988), but 
analysis of later stage placentae, when m/p4 is produced have not t)een 
published. 
Other placental GH/PRL family members, including the mouse placental 
lactogens I and II, and at least 10 prolactin like proteins (PLPs) (Dai et al., 1996; 
Deb et al., 1991; Deb and Scares, 1990; Deb et al., 1989; Lin et al., 1997a; Lin 
et al., 1997b; Muller et al., 1998a; Muller et al., 1998b) are also expressed in 
particular tissue specific and temporal patterns during gestation (Soares et al., 
1998). While differences have been noted in the ability of mPLs I and II to effect 
gene expression in the mammary gland and corpus luteum through interaction 
with PRL receptors-, much less is known about the reason for differential pip 
gene regulation. One pip family member has been shown to bind to natural killer 
cells and to prevent cytolytic activities of natural killer cells within the decidua 
(Muller et al., 1999). Thus, the mrp/plfs and the pips represent at least 13 
different non-classical GH/PRL related genes in the mouse placenta whieh-that 
are regulated in different ceil and temporal specific pattems. Determining the 
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functions of these proteins, and how spatial and temporal regulation of these 
genes relates to function will be important for gaining a better understanding of 
mammalian reproduction. 
Potential mechanisms of tissue specific variation in m/p/p/f expression 
The mechanisms by which mqj/plf genes express in particular cells or 
tissues are also of interest. Much work has been done in cultured cells using 
different m/p/p/f promoters to understand gene expression in response to 
mitogens or serum. Prior to this work it was not completely understood which 
mrp/plfs were expressed in the placenta, nor which promoters produced the 
mRNAs expressed in the placenta or in 3t3-3T3 cells.Therefore, analysis of 
mrp/plf promoter activity in cultured cells, while valuable in contributing to 
understanding transcriptional regulation in response to mitogens, could not be 
compared to activity of the endogenous promoters to gain a understanding of 
these genes in a physiological context. In this work, the promoters for each 
expressed mrp/plf gene have been identified as well as sites of tissue specific 
expression. The promoter known as plf42, which is activated by serum in a 
transfected liver cell line (Linzer and Mordacq, 1987), is the promoter for p/ft. 
The promoter known as plf149, which is not stimulated by serum in transfected 
liver cells (Linzer and Mordacq, 1987), is the promoter for mrp4. The promoter 
for mrp3 was already identified as being contiguous with the remainder of the 
mrp3 gene (Connor et al., 1989). 
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The upstream region of mrp3 contains an FGF response element that 
allows it to be specifically activated in response to FGF while the other two 
promoters are not activated (Mohideen et al., 1999). Despite 98% homology in 
the sequenced regions of these promoters, each promoter is regulated differently 
from the other in response to particular stimuli. These differences in activity have 
been shown to be the result of slight alterations in nucleotide sequence that 
result in different cis-acting elements. While the physiological significance of 
these differences of transfected promoter activity in response to treatment are 
unknown, the demonstration of tissue specific and temporal regulation of these 
genes will allow analysis of these differences in comparison to the physiologic 
context in which these genes are expressed. 
Although caution should be exercised when comparing the regulation of 
transfected promoters to the regulation of endogenous genes, some of the 
results obtained regarding expression patterns of endogenous mrp/plf genes 
encourage speculation. For instance, the specific FGF response element found 
in the mrp3 gene might be correlated with the specific expression of mrp3 in 
healing skin wounds. In healing wounds or in the cycling hair follicle, expression 
and functions of members of the FGF family including bFGF (Ortega et al., 
1998), FGF5 (Suzuki et al., 2000), and particularly KGF (Werner et al., 1992; 
Werner et al., 1994) have been demonstrated. Furthermore, in chapter four it 
was demonstrated that KGF stimulates mrp/p/f synthesis in primary cultures of 
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keratinocytes, suggesting that members of the FGF family might stimulate 
mrp/plf synthesis in healing wounds. It is possible that this stimulation occurs in 
part through the specific FGF response element previously identified in 
transfected 3T3 cells. 
However, there is clearly more to regulation of the endogenous mrp/plf 
genes than in the first 350 basepairs of upstream sequence. This is illustrated 
by the demonstration that 1510 basepairs of mrp3 upstream sequence fails to 
direct detectable reporter gene expression to the placenta in transgenic embryos 
(chap 5) and that 3t3-3T3 cells produce predominantly plf1 In response to bFGF 
stimulation (chap 2). even though the mrp3 promoter is stimulated by bFGF in 
transfected cells. Further complicating the issue is that a post-transcriptional 
nuclear mechanism has been determined for the FGF induced increase in plf1 
expression (Mohideen, 1995), suggesting that the p/ff promoter is constitutively 
active In these cells. M/p3 Is also expressed at low levels in 3T3 cells, but it is 
not known whether endogenous mqy3 is regulated transcriptionally or post-
transcriptionally, due to the relatively low abundance of mrp3 mRNA in 
comparison to plf1 in 3T3 cells. 
What and where are the differences between these genes that allow mrp3 
to be the most abundant mrp/plf \t\ skin wounds and the placenta, mrp4 to be the 
most abundant in the ear and tail, and pifl to be most abundant in 3T3 cells and 
the alimentary tract. This problem may be approached from different strategies. 
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One could ask, for instance, If particular transcription factors affect individual 
rnqj/plf genes differently. Proteins that have been shown to play a dramatic role 
in mrp/^ /f expression In the placenta are GATA factors, for which there are 
binding sites in the promoters. While direct activation of the mrp/plf 
promoters has not been demonstrated, functional knockouts of GATA factors, 
especially GATA 2, decrease /n^p/f expression up to 80% (Ma et al., 1997). It is 
likely that GATA factors effect mrp3 expression, because this is the predominant 
form in the placenta, and such a dramatic decrease would not be seen if mrp3 
were not affected. It is not known however, if expression of each mrp/plf \s 
effected equally by GATA factors. Nor is it clear if GATA factors directly interact 
with the mrp/plf promoters or if they activate expression of some other gene that 
stimulates mrp/plf expression. It would be fairly simple to use the RT-PCR 
restriction digest assay described in this work to determine if GATA factors 
specifically regulated a particular mrp/plf, or affected all mrp/plfs equally. It would 
also be possible to transfect GATA factors or other placental transcription factors 
into 3T3 cells to determine if different mrp/plfs could be induced, or measure the 
activity of the different m/p/p/f promoter constructs in response to co-transfected 
transcription factors. These kinds of experiments could identify proteins that are 
involved in the differential expression of the mrp/plf genes. Other transcription 
factor knockouts have also been created that could-affect m/p/p^expression 
including cJun, cEBP, and c-ETs-2 for which there are binding motife in the 
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mrp/p/f promoters. The relative and total levels of each mrp/plf\n knockout mice 
could provide valuable information on how these genes are regulated tissue 
specifically. 
The second way to identify mechanisms involved in differential mrp/plf 
expression is to compare the effects of the sequences surrounding each mrp/plf 
gene on cell type specific expression. In cell culture, upstream sequences of up 
to -650 b.p. have been used to identify elements involved in response to various 
growth factor or hormone treatments (Mohideen et al., 1999). In this case, 
sequences involved in differential regulation by growth factors were easily 
identified because the mrp/plf genes are highly identical. These genes could 
thus become very useful tools in studying transcriptional regulation, because 
each gene already contains mutations that differentially effect growth factor or 
cell type specific expression. 
To determine if the sequences surrounding the mrp/plf genes contain 
elements involved in cell specific expression, the overall levels of expression, 
relative to a cotransfected reporter, should be measured for each promoter in 
each cell type to be tested. This analysis could be done in stably transfected 
keratinocyte cell lines, trophoblast cell lines, or 3T3 cells. This kind of analysis 
could possibly identify promoter elements involved in cell specific expression of 
mrp/plf t^ pes. However, the best way to analyze the mrp/plf genes for elements 
contributing to cell or tissue specific expression in the context of which they are 
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expressed would be to analyze the activity of different promoters in 
transgenic mice. This analysis was initiated using the mrp3 promoter in the 
research presented here. 
Analysis of the mrp3 promoter in transgenic mice 
As demonstrated in chapter 5, 1514 basepairs of mrp3 promoter along 
with 3.6 kb of 3' sequence is not sufficient to express detectable reporter gene 
expression In the placentae of transgenic embryos. These results are further 
evidence for the contribution of as yet unidentified sequences to endogenous 
/77Ap/p/f expression. Addition of the CMV enhancer to the 5' end of the gene 
however, did allow tissue specific expression of the m/p3 promoter when 3 kb of 
mrp3 downstream sequence was present at the 3' end of the lacZ gene. These 
results suggest two important aspects of mrp3 regulation. First, the mqjS 
promoter requires an enhancer to be expressed in vivo. The enhancer element 
is evidently not present in the sequences immediately surrounding the coding 
sequences of the mrp3 gene. This requirement is somewhat similar to the human 
growth hormone gene cluster, which is regulated by a locus control region and a 
series of DNAse hypersensitive sites located 15 to 30 kb away from the most 5' 
gene. (Jones et al.. 1995). Second, a 1514 basepair mrp3 sequence including 
the mrp3 promoter, and the 3' 3.6 kb non-coding region of the mrp3 gene contain 
regulatory elements capable of directing tissue specific expression of the 
transgene, but only in the presence of an additional enhancer. It is particularly 
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interesting that, although the CMV enhancer is active throughout the developing 
fetus (Baskar et al., 1996), the mrp3 sequences are able to not only direct giant 
cell expression, but to prevent expression in non-giant cells. Thus, to better 
understand cell specific expression of mrjp/pHs, it will be important to identify the 
endogenous enhancers for the mrp/plf&, as well as determine how the more 
proximal sequences are able to direct tissue specificity in the presence of an 
enhancer. 
Finding endogenous m/p/pif enhancers 
As a first step towards analyzing further sequences of the mrp/ptfqen&s 
for enhancers, cosmids containing each mrp/plfqene have been identified. The 
identification of cosmids containing individual mrp/pHs will be very useful for 
investigating the differential regulation of these genes. For instance, it will now 
be possible to stably transfect a non-mouse trophoblast cell line (such as RCHO 
cells) with individual cosmids, and correlate expression of mrp/pHs with ONAse 
hypersensitve sites specifically induced upon giant cell differentiation. This could 
provide evidence of a giant cell specific enhancer. Whereas identification of 
DNAse hypersensitive sites in mouse cells containing the cluster of highly 
homologous mrp/plf genes would be rather complicated due to the high 
homology and multitude of shared restriction sites for each mrp/plf, the analysis 
of one 40 kb fragment at a time containing a known mrp/plf would more easily 
define the location of a DNAse hypersensitive site. It will also be possible to co-
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transfect cells with equal amounts of different mrp/plf cosvnids and determine, 
using the diagnostic RT-PCR assay, if there are specific elements within those 
cosmids that enable a particular gene to be more active. Larger upstream 
regions containing potential regulatory elements could then be subcloned and 
tested in transgenic mice for tissue specific expression. 
Tissue specific expression with a ubiquitous enhancer 
While the results presented in chapter 5 suggest that an enhancer is 
required for mrp3-promoter activity in vivo, these results also show that the 1514 
b.p. of upstream and 3.6 kb downstream mrp3 sequence are able to direct tissue 
specific expression. How do the mrp3 sequences direct tissue specific 
expression in the presence of the CMV enhancer? In most models of 
transcriptional regulation by enhancers, transcription factors bound to the 
enhancer interact with trans-acting factors associated with the promoter to 
increase transcriptional initiation by RNA polymerase II. Some models suggest 
that the main function of enhancers is to overcome inhibitory chromatin structure 
at weak promoters (Majumder and OePamphilis, 1995), and allow an open 
chromatin structure in which RNA pol 11 may more easily bind. Other models 
suggest that enhancers may recruit transcription factors and coactivators that 
then loop to contact and activate the RNA pol II machinery at the promoter 
(Blackwood and Kadonaga, 1998). Both of these models may occur to some 
degree. If these models are applied to the CMV/mrp3 transgene expression 
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during midgestation, the results would suggest that the CMV enhancer Is best 
able to functionally interact with the mrp3 promoter in giant cells, and that the 
likelihood of this interaction occurring is effected by the mrp3 promoter sequence 
included in the transgene, as well as surrounding chromatin structure at the 
transgene insertion site. Evidence is provided here which suggests that 
elements within the surrounding mrp3 sequences can prevent CMV induced 
activity of the promoter in non-giant cells. When the 3' 3kb fragment is removed 
from the mrp3 transgene construct, expression becomes more aberrant, and in 
some cases giant cell expression is lost. This result suggests that some tissue 
specific regulation is associated with the 3' 3kb fragment. Furthermore, in 
transfected COS cells, and also in transgenic embryos, as upstream sequences 
are removed from the 5' end of the mrpS gene, expression levels and non­
specific expression of the transgene increases respectively. These results 
suggest that 5' sequences may also inhibit functional interaction with the mrp3 
promoter. 
How do these 5' or 3' sequences inhibit the CMV enhancer from 
interacting with the mrp3 promoter? In the hGH family placental members, 
pituitary expression is repressed by specific elements in the 5' ends of the 
genes, as well as the 3' end(Nachtigal et al., 1993). Curiously, the same 
repressor in the 3' end acts as an enhancer of placental expression.(Jiang and 
Eberhardt, 1997). Another possible reason that the mqp3 5' sequences inhibit 
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CMV promoter activity could t>e that the probability of interaction with the 
enhancer is decreased simply because of the increased distance between the 
mrp3 promoter and the enhancer. For this reason, it will t)e important to mutate 
or replace elements of the mrp3 gene that are suspected of being involved in 
tissue specific expression, rather than remove them. These elements could 
include GATA factor binding elements, the AP-1 sites, AP-2 site, or the FGF 
response element, all which are involved in either giant cell gene expression (Ma 
et a!., 1997; Schorpp-Kistner et al., 1999; Shi et al., 1997) or have t}een 
demonstrated to effect m/73/p/f expression (Mohideen et al., 1999). 
Mrp3 upstream sequences effect splicing of the transgene 
Another explanation as to how mrp3 sequences may play a role in 
promoter activity in the presence of the CMV enhancer is suggested by analysis 
of the RNA produced by different deletion constructs. In transfected cells, it was 
demonstrated that the presence of the upstream region of the mrp3 gene 
represses expression of reporter gene activityT and decreases splicing of a 
downstream heterologous intron. It was also demonstrated that RNA transcripts 
originating further upstream than the most 3' transcriptional start site contained a 
lower ratio of spliced to unspliced transcripts than of transcripts that began after 
the normal start site. This suggests that there are upstream promoters that can 
produce non-functional transcripts. It is thus possible that upstream promoters 
compete for interaction with the CMV enhancer. It would then follow, that, in the 
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tissues in which expression of the transgene is demonstrated, a promoter which 
results in functional transcripts is being chosen over other possible promoters. 
Thus, in the absence of tissue specific transcription factors, mrp3 sequences 
could prevent non-tissue specific expression in the presence of a ubiquitous 
enhancer by competing for or actively preventing enhancer activity from 
interaction with the correct promoter. In support of this model, it is demonstrated 
that the ratio of spliced to unspliced heterologous intron is increased in isolated 
keratinocytes when compared to whole skin, while the intron is completely 
spliced in the whole skin of mouse containing the transgene missing the 
upstream promoters of the mrp3 gene. Splicing is also higher in skin containing 
cycling hair follicles than in the heart of the same mouse. While further 
experiments must be done to demonstrate that upstream promoters are acting 
as functional repressors through competition and the production of nonsense 
transcripts, this is a model that could account for what appears to be post-
transcriptional regulation of the plf1 message, but transcriptional regulation of 
transfected promoters. If, in 3T3 cells, there is an enhancer that is constitutively 
active, and is competed for by functional and decoy promoters, it is possible that 
stimulation with mitogens could increase expression or activation of transcription 
factors or accessory factors that favor activation of the correct promoter. 
Mitogen stimulated transcription factors could increase MRP/PLF expression 
through occlusion of the decoy promoter(s), by specifically derepressing the 
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correct promoter, and/or by actively recruiting enhancer activity or RNApol II to 
the correct promoter. In the whole mouse or embryo, nuclear run-off analysis of 
the mrp/plf genes has not been reported. However, when mouse embryo cells 
are dispersed, there is no difference in transcription levels of mqj/plfs between 
these primary non-mrp/plf producing cultures, and 3T3 cells, which produce high 
levels of plf1 (Malyankaret al., 1994; Malyankar et al., 1996). Thus, it is possible 
that this type of regulation is occum'ng in intact mouse tissues as well. 
Competition between promoters for enhancer activity has been suggested as a 
mechanism by which the genes which comprise the globin locus are regulated by 
the locus control region (Choi and Engel, 1988), and a similar process has 
recently been demonstrated in Drosophila, by which one upstream evenskipped 
promoter acts as a boundary element for activation of a further downstream 
evenskipped promoter (Ohtsuki and Levine, 1998). Furthermore, multiple 
altemate upstream initiation sites have been demonstrated on many genes, 
including the prolactin promoter. 
Typically altemate promoters result in either a longer 5' untranslated 
region or an extra exon that may or may not be translated. But what happens to 
transcripts that originate from upstream promoters with translational start codons 
that result in nonsense containing transcripts? The results presented here 
suggest that these transcripts may either not be spliced or may be degraded 
soon after splicing, resulting in a higher ratio of unspliced to spliced message. In 
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most eukaryotic organisms that have t)een examined, transcripts containing 
nonsense mutations that are upstream of an intron are degraded either in the 
cytoplasm (yeast) or in the nucleus (mammals) (Hentze and Kulozik, 1999; 
Maquat, 1995). So, it is possible that spliced transcripts from upstream 
promoters such as mrp3 are degraded in the nucleus and that the apparent 
increase in relative levels of unspliced message from upstream promoters is the 
result of a lower stability of the spliced nonsense containing transcripts. This 
provides the basis for a fine tuning mechanism of transcriptional regulation 
(figure 1) by which transcription factors or enhancers with a high potential to 
Induce transcription could be present on a gene and still not result in functional 
transcripts unless particular transcription factors direct RNA polymerase activity 
to the correct promoter. The implications of this could be important not only to 
understanding mrp/p  ^regulation, but eukaryotic gene regulation in general, as it 
would suggest a previously unrecognized mechanism of gene regulation which 
could largely go unnoticed, because the transcripts from decoy promoters would 
be degraded rapidly. In fact, it has been determined that 95% of RNA pol II RNA 
transcribed in the nucleus is also degraded in the nucleus. While a large portion 
of this degradation is accounted for by removal and degradation of introns 
(-^80%), it has been estimated that only a third of exon containing RNA makes it 
out of the nucleus as well (Brandhorst, 1974; Jackson et al., 2000; Soeiro, 
1968). Thus, nuclear RNA decay appears to be a very important level of gene 
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A. Promoter not accessible in absence of enhancer 
• 
B. Nonsense promoter usage in absence of tissue specific factors 
CMV 
Nonsense transcript 
degraded in the 
nucleus 
TATA I TATA 2 
G. Tissue specific factors mediate correct promoter usage 
CMV 
Functional 
transcript 
TATA 2 TATA 1 
198 
regulation of which relatively little is understood. For that reason, it will be 
important to follow up these results with experiments that will conclusively 
demonstrate what is happening to upstream nonsense containing transcripts in 
regards to stability and splicing. It will be even more important to determine if 
this mechanism is actually occurring on the endogenous mrp/plf genes, and to 
determine how many other genes this mechanism may effect. 
To determine if the mrp3 upstream transcripts are degraded by the 
nonsense mediated decay pathway, it will be necessary to inhibit nonsense 
mediated decay, and examine the levels and splicing of upstream nonsense 
transcripts. This can be done by cotransfecting the mrp3 constructs described 
here with a dominant negative form of the UPF-1 gene. The wild type form of this 
gene encodes a human homologue of a yeast protein known to be involved in 
nonsense mediated RNA decay, while a mutant fomn, which has a cysteine to 
arginine mutation acts as a dominant negative and has been shown to abrogate 
nonsense mediated decay (Sun et al., 1998). An increase in spliced message 
from upstream transcripts in the presence of dominant negative UPF-1, but not 
wild type UPF-1, would be evidence that the nonsense mediated decay pathway 
is involved in removing spliced transcripts from upstream promoters. This 
analysis could also be performed on endogenous mrp/plf message by stably 
transfecting or transiently transfecting high levels of wild type or dominant 
negative UPF-1 into 3T3 cells, and assaying for levels of upstream transcripts. 
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This could even be done in transgenic mouse embryos by ubiquitously 
expressing high levels of dominant negative UPF-1, and assaying RNA from the 
embryo proper for mrp/p/f levels. Clearly there are many experiments that could 
be designed to investigate this phenomenon, including mutation of upstream 
promoters, removal of translatlonal start codons from upstream regions, and 
removal of introns, all which could provide evidence for the model suggested. 
Though more work is needed to understand how the mrp3 upstream sequences 
are involved in splicing, I believe that dissection of this mechanism could provide 
a useful contribution to the study of gene regulation. 
In conclusion, it has been demonstrated that three members of the mrp/plf 
gene family are regulated in different tissue and temporal specific patterns. The 
finding that these genes are differentially expressed in adult epithelia suggests 
further functions than those previously proposed for placental mrp/plf. It is also 
now clear that while proximal regions of the mrp3 gene may be involved in tissue 
specific expression, an enhancer is necessary for the high level expression 
demonstrated for the endogenous mrp/plf genes in the placenta. Finally a model 
is provided which suggests how tissue specific expression in the presence of a 
strong ubiquitous enhancer might t)e achieved. This model also reconciles 
observed discrepancies between interpretations of studies of post transcriptional 
regulation of endogenous m/p/p/f transcripts and studies of transcriptional control 
of transfected promoters. Identification of functions for different mrp/plf genes in 
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different tissues, and characterization of the endogenous enhancer(s) and how It 
interacts with the proximal m/p/p/f promoters to regulate expression should now 
be the focus of studies following this work. 
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APPENDIX 
IDENTIFICATION OF PROMOTERS FOR THE MRP/PLF GENES 
Materials/Methods 
Cosmids containing mrp/plf hybridizing sequences (kindly provided by Dan 
Linzer) as well the mrp3 gene from -1450 to + 300 basebairs past the poly A site 
( kindly provided by Dave Denhardt) and genomic DMA, were amplified using 
primers which recogni2e from exon 3(+307 to +332) 
acaaaagccccatgagatgcaatac and from exon 4 5'actcactagatcgtccagagg3' (-<'453 
to+433). PGR amplified fragments were then digested wrth EcoRI for four hours 
at 37°C, then digested with either BsoFI or BstXI as before. The fragments were 
analyzed on a 2% gel. Clones which produced per products which digested in a 
pattern consistent with a particular mrp/plf cDNA were sequenced across the 
promoter region using a primer (ue1-2 caggagcatggttgaatcg) which recognized 
the 5' end of the three mrp/plfs identified so far. 
Identification of the mrp4 and pifl promoter 
To identify the mrp4 promoter a series of cosmid clones were screened 
for the presence of the mrp4 gene by several PCR based assays. First, 
diagnostic PCR was performed between exons 3 and 4 on isolated cosmid 
clones containing mrp/p^ hybridizing genes in order to identify specific mrp/plf 
containing cosmids. As shown in figure 1, individual clones were identified which 
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produced the predicted restriction digest pattern for each of the mrp/plfe. Of six 
cosmids which contained a full length mrp/plf gene, two gave patterns specific for 
plf1, one digested as plf2, two gave mrp3 specific patterns, and one digested as 
would be expected for mrp4. Clones which produced PCR products that gave 
mrp/p/f specific digestion patterns were used as templates for PCR and 
sequencing across the promoter region. By this method, the promoter known as 
plf42 was shown to correspond to pifl, the promoter plf149 corresponded to 
mrp4, and the mrp3 promoter corresponded to mrp3 cDNA. The cosmid 
containing the plf2 gene appeared to contain a promoter with the same 
sequence as mrp3, however, because a cell type or tissue which expressed 
exclusively plf2 was not available to confirm the linkage, it is possible that the 
promoter sequence identified in the cosmid as mrp3 is not contiguous with the 
plf2 gene. To confirm that the promoter regions were actually contiguous with the 
genes encoding the different mRNAs, RT-PCR was performed using a 5' primer 
which would amplify transcripts initiating at upstream promoters located between 
140 or 230 basepairs of the normal transcriptional start site(not shown). When 
performed on the tail, the promoter for mrp4 was confirmed to be plf149. 
Similarly, 3t3 cells, which produce predominantly plf1, produced upstream 
transcripts which corresponded to the plf42 promoter, and the placental mrp3 
cONA, was linked to the mrp3 promoter, as expected. 
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 ^cosi COS 2 cos 4 
^ E EF EX E EF EX E EF EX 
cos6 gDNA pMRP3 
E EFEX E EFEX E EFEX 
Figure 1 
